1
|
Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I, Paris I, Pinto C, De Placido S. Aromatase inhibitors: the journey from the state of the art to clinical open questions. Front Oncol 2023; 13:1249160. [PMID: 38188305 PMCID: PMC10770835 DOI: 10.3389/fonc.2023.1249160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Accepted: 11/30/2023] [Indexed: 01/09/2024] Open
Abstract
Breast cancer is a major cause of death among females. Great advances have been made in treating this disease, and aromatase inhibitors (AIs) have been recognized as the cornerstone. They are characterized by high efficacy and low toxicity. The authors reviewed the available literature and defined state-of-the-art AI management. This study was designed to assist clinicians in addressing the need to equally weigh patients' needs and disease control rates in their everyday clinical practice. Today, AIs play a central role in the treatment of hormone receptor-positive breast cancer. In this study, an expert panel reviewed the literature on the use of AIs, discussing the evolution of their use in various aspects of breast cancer, from pre- and postmenopausal early breast cancer to metastatic breast cancer, along with their management regarding efficacy and toxicity. Given the brilliant results that have been achieved in improving survival in everyday clinical practice, clinicians need to address their concerns about therapy duration and the adverse effects they exert on bone health, the cardiovascular system, and metabolism. Currently, in addition to cancer treatment, patient engagement is crucial for improving adherence to therapy and supporting patients' quality of life, especially in a selected subset of patients, such as those receiving an extended adjuvant or combination with targeted therapies. A description of modern technologies that contribute to this important goal is provided.
Collapse
Affiliation(s)
- Daniele Generali
- Breast Cancer Unit, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy
- Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy
| | - Rossana Berardi
- Medical Oncology, Azienda Ospedaliera Universitaria (AOU) delle Marche, University Politecnica delle Marche, Ancona, Italy
| | - Michele Caruso
- Humanitas Istituto Clinico Catanese, Breast Centre Humanitas Catania, Catania, Italy
| | - Marina Cazzaniga
- School of Medicine and Surgery University of Milano Bicocca, Milan, Italy
- Phase 1 Research Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, Monza, Italy
| | - Ornella Garrone
- Medical Oncology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Ida Minchella
- Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy
| | - Ida Paris
- Department of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy
| | - Carmine Pinto
- Medical Oncology Unit, Comprehensive Cancer Centre, Azienda Unità Sanitaria Locale - Istituto di Ricerca e Cura a Carattere Scientifico (AUSL-IRCCS) di Reggio Emilia, Reggio Emilia, Italy
| | - Sabino De Placido
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| |
Collapse
|
2
|
Young NA, Hampton J, Sharma J, Jablonski K, DeVries C, Bratasz A, Wu LC, Lustberg M, Reinbolt R, Jarjour WN. Aromatase-Inhibitor-Induced Musculoskeletal Inflammation Is Observed Independent of Oophorectomy in a Novel Mouse Model. Pharmaceuticals (Basel) 2022; 15:ph15121578. [PMID: 36559029 PMCID: PMC9785754 DOI: 10.3390/ph15121578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 12/09/2022] [Accepted: 12/14/2022] [Indexed: 12/23/2022] Open
Abstract
Aromatase Inhibitors (AIs) block estrogen production and improve survival in patients with hormone-receptor-positive breast cancer. However, half of patients develop aromatase-inhibitor-induced arthralgia (AIIA), which is characterized by inflammation of the joints and the surrounding musculoskeletal tissue. To create a platform for future interventional strategies, our objective was to characterize a novel animal model of AIIA. Female BALB/C-Tg(NFκB-RE-luc)-Xen mice, which have a firefly luciferase NFκB reporter gene, were oophorectomized and treated with an AI (letrozole). Bioluminescent imaging showed significantly enhanced NFκB activation with AI treatment in the hind limbs. Moreover, an analysis of the knee joints and legs via MRI showed enhanced signal detection in the joint space and the surrounding tissue. Surprisingly, the responses observed with AI treatment were independent of oophorectomy, indicating that inflammation is not mediated by physiological estrogen levels. Histopathological and pro-inflammatory cytokine analyses further demonstrated the same trend, as tenosynovitis and musculoskeletal infiltrates were detected in all mice receiving AI, and serum cytokines were significantly upregulated. Human PBMCs treated with letrozole/estrogen combinations did not demonstrate an AI-specific gene expression pattern, suggesting AIIA-mediated pathogenesis through other cell types. Collectively, these data identify an AI-induced stimulation of disease pathology and suggest that AIIA pathogenesis may not be mediated by estrogen deficiency, as previously hypothesized.
Collapse
Affiliation(s)
- Nicholas A. Young
- Department of Internal Medicine, Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
| | - Jeffrey Hampton
- Department of Internal Medicine, Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
| | - Juhi Sharma
- Department of Internal Medicine, Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
| | - Kyle Jablonski
- Department of Internal Medicine, Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
| | - Courtney DeVries
- Department of Medicine, WVU Cancer Institute, WVU Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA
| | - Anna Bratasz
- Small Animal Imaging Core, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
| | - Lai-Chu Wu
- Department of Internal Medicine, Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
- Department of Biological Chemistry and Pharmacology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
| | - Maryam Lustberg
- Smilow Cancer Hospital/Yale Cancer Center, New Haven, CT 06519, USA
| | - Raquel Reinbolt
- Department of Internal Medicine, The James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
| | - Wael N. Jarjour
- Department of Internal Medicine, Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
- Correspondence: ; Tel.: +1-614-366-7016; Fax: +1-614-366-0980
| |
Collapse
|
3
|
Andreu Y, Soto-Rubio A, Ramos-Campos M, Escriche-Saura A, Martínez M, Gavilá J. Impact of hormone therapy side effects on health-related quality of life, distress, and well-being of breast cancer survivors. Sci Rep 2022; 12:18673. [PMID: 36333362 PMCID: PMC9636256 DOI: 10.1038/s41598-022-22971-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2022] [Accepted: 10/21/2022] [Indexed: 11/06/2022] Open
Abstract
To explore the modulatory role of Adjuvant Hormone Therapy (AHT) on health-related quality of life (QoL), subjective well-being and distress prevalence in Breast Cancer (BC) survivors, considering the survival phase. Cross-sectional study with control group. 616 BC survivors participated. Examination of interaction effect between AHT and time since end of primary treatment showed that many of the positive changes observed through the survival phases were experienced exclusively by survivors without AHT. When AHT was not prescribed, longer time elapsed was associated with a decrease in distress prevalence and an improvement in subjective well-being and QoL. It seems there is a turning point around the fifth year after finalization of primary treatment, from which the survivors without AHT significantly improve in several areas and those with AHT do so to a lesser extent. It is expected that the improvement in QoL throughout the different survival phases will have a significant impact on the adherence and maintenance of AHT and, consequently, the likelihood of survival. Thus, AHT side-effects should be routinely assessed by health care providers to gain accurate knowledge that allows improving the QoL of BC survivors.
Collapse
Affiliation(s)
- Y. Andreu
- grid.5338.d0000 0001 2173 938XPersonality, Assessment and Psychological Treatments Department, Faculty of Psychology, University of Valencia, Valencia, Spain
| | - A. Soto-Rubio
- grid.5338.d0000 0001 2173 938XPersonality, Assessment and Psychological Treatments Department, Faculty of Psychology, University of Valencia, Valencia, Spain
| | - M. Ramos-Campos
- grid.453328.bAsociación Española Contra el Cáncer (AECC), Valencia, Spain
| | - A. Escriche-Saura
- grid.453328.bAsociación Española Contra el Cáncer (AECC), Valencia, Spain
| | - M. Martínez
- grid.411308.fDepartment of Medical Oncology, Hospital Clínico Universitario de Valencia-Biomedical Research Institute INCLIVA, Valencia, Spain
| | - J. Gavilá
- grid.418082.70000 0004 1771 144XMedical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain
| |
Collapse
|
4
|
Akin Telli T, Ozturk MA, Alan O, Hasanov R, Kostek O, Arikan R, Basoglu T, Kaya S, Ercelep O, Akgul Babacan N, Dane F, Yumuk PF. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy. Future Oncol 2022; 18:2425-2439. [PMID: 35695547 DOI: 10.2217/fon-2021-1322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Objective: The aim of this study was to investigate quality-of-life (QoL) in breast cancer (BC) patients treated with adjuvant endocrine therapy (AET). Methods: We designed a cross-sectional study of 233 BC patients treated with AET and used the Functional Assessment of Cancer Therapy - Breast questionnaire. Results: No significant difference was observed between endocrine agents. Duration of AET did not affect QoL. In the entire cohort, multivariate analysis determined age (p = 0.034) and switching treatment from tamoxifen to aromatase inhibitors (p = 0.049) as significant positive coefficients of QoL, while comorbidity (p = 0.072) tended to be associated with lower scores. Education level (p = 0.001) and chemotherapy (p = 0.04) were significant predictors of QoL in the tamoxifen group, while comorbidity (p = 0.04), surgery type (p = 0.02), radiotherapy (p = 0.006) and stage (p = 0.009) had a significant impact on QoL in aromatase inhibitors group. Conclusion: Evaluating the well-being of BC patients by QoL questionnaires is of great importance to identify particular subgroups that may require supportive care.
Collapse
Affiliation(s)
- Tugba Akin Telli
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Mehmet Akif Ozturk
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Ozkan Alan
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Rahib Hasanov
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Osman Kostek
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Rukiye Arikan
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Tugba Basoglu
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Serap Kaya
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Ozlem Ercelep
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Nalan Akgul Babacan
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Faysal Dane
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Perran Fulden Yumuk
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| |
Collapse
|
5
|
Park C, Park SK, Woo A, Ng BP. Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study. Qual Life Res 2022; 31:1345-1357. [PMID: 35064415 DOI: 10.1007/s11136-021-03059-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/02/2021] [Indexed: 01/05/2023]
Abstract
OBJECTIVES The evidence regarding the impact of individual adjuvant endocrine therapies (AET) on health-related quality of life (HRQoL) is limited. We aimed to assess the association between the type of AET and HRQoL and to examine the relationship between HRQoL and one-year mortality among women with breast cancer in the USA. METHODS This retrospective cross-sectional study used the 2006-2017 Surveillance, Epidemiology, and End Results (SEER)-Medicare Health Outcomes Survey database to identify older women with early-stage hormone receptor-positive breast cancer. Multivariate linear regressions were used to assess the association between types of AET (anastrozole, letrozole, exemestane, and tamoxifen) and HRQoL scores (physical component summary (PCS) and mental component summary (MCS)). Multivariate logistic regressions were used to predict the impact of PCS and MCS on one-year mortality. RESULTS Out of 3537 older women with breast cancer, anastrozole was the most commonly prescribed (n = 1945, 55.0%). Regarding PCS, there was no significant difference between the four AET agents. Higher MCS scores, which indicate better HRQoL, were reported in patients treated with anastrozole (vs. letrozole [β = 1.26, p = 0.007] and exemestane [β = 2.62, p = 0.005) and tamoxifen (vs. letrozole [β = 1.49, p = 0.010] and exemestane [β = 2.85, p = 0.004]). Lower PCS and MCS scores were associated with higher one-year mortality, regardless of type of AET initiated, except for tamoxifen in MCS. CONCLUSION Although there was no significant difference in physical HRQoL scores between AET agents, anastrozole and tamoxifen were associated with better mental HRQoL scores.
Collapse
Affiliation(s)
- Chanhyun Park
- Health Outcome Division, The University of Texas at Austin College of Pharmacy, 2409 University Avenue MC A1930, Austin, TX, 78712-1120, USA.
| | - Sun-Kyeong Park
- School of Pharmacy, The Catholic University of Korea, Bucheon, South Korea
| | - Ahye Woo
- Department of Pharmacy and Health Systems Sciences, School of Pharmacy, Northeastern University, Boston, MA, USA
| | - Boon Peng Ng
- College of Nursing, University of Central Florida, Orlando, FL, USA
- Disability, Aging, and Technology Cluster, University of Central Florida, Orlando, FL, USA
| |
Collapse
|
6
|
Di Meglio A, Soldato D, Presti D, Vaz-Luis I. Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy. Curr Opin Oncol 2021; 33:553-573. [PMID: 34456250 DOI: 10.1097/cco.0000000000000781] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
PURPOSE OF REVIEW A comprehensive approach to survivorship care for women with early-stage, hormone-receptor positive breast cancer should systematically include the proactive assessment and adequate management of endocrine therapy-associated symptoms, in order to assure optimal balance between preserving quality of life (QOL) and maximizing treatment adherence. We reviewed the recent literature focused on lifestyle factors, including physical activity, diet and nutrition, weight management, smoke, and alcohol behavior, and their link with symptomatology and QOL among women receiving adjuvant endocrine therapy. RECENT FINDINGS Recent studies confirm the safety, feasibility, and effectiveness of lifestyle interventions in mitigating several common endocrine therapy-related effects, including musculoskeletal pain, fatigue, and insomnia, and in improving physical and emotional wellbeing as well as overall health-related QOL among women with early-stage breast cancer. SUMMARY Healthy lifestyle behaviors have the potential to modulate the downstream impact of endocrine therapy and improve QOL among women with early-stage breast cancer. Considerations for real-world clinical care implementation emerged, including a need to evaluate the long-term uptake of healthy behaviors and facilitate the postintervention maintenance of an improved lifestyle. Some facilitators to health promotion in breast cancer survivors were also suggested, such as individualized and one-to-one supervised programs, and digital solutions providing real-time feedback, building on personalized, direct patient engagement.
Collapse
Affiliation(s)
- Antonio Di Meglio
- Molecular predictors and new targets in oncology, INSERM Unit 981, Gustave Roussy, Villejuif
| | - Davide Soldato
- Molecular predictors and new targets in oncology, INSERM Unit 981, Gustave Roussy, Villejuif.,Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genova, Genova
| | - Daniele Presti
- Molecular predictors and new targets in oncology, INSERM Unit 981, Gustave Roussy, Villejuif.,Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy
| | - Ines Vaz-Luis
- Molecular predictors and new targets in oncology, INSERM Unit 981, Gustave Roussy, Villejuif
| |
Collapse
|
7
|
Bichoo RA, Mishra A, Lal P, Gyan C, Agarwal G, Agarwal A, Mishra SK. Quality of Life (QoL) in Postmenopausal Breast Cancer Patients Receiving Adjuvant Hormonal Therapy. Indian J Surg 2021. [DOI: 10.1007/s12262-021-02766-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
|
8
|
Sheng JY, Santa-Maria CA, Blackford AL, Lim D, Carpenter A, Smith KL, Cohen GI, Coughlin J, Appel LJ, Stearns V, Snyder C. The impact of weight loss on physical function and symptoms in overweight or obese breast cancer survivors: results from POWER-remote. J Cancer Surviv 2021; 16:542-551. [PMID: 34018096 DOI: 10.1007/s11764-021-01049-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Accepted: 04/20/2021] [Indexed: 01/02/2023]
Abstract
PURPOSE In pre-planned observational analysis of the POWER-remote trial, we examined the impact of weight loss on patient-reported outcomes (PROs). We hypothesized a priori that survivors with ≥ 5% weight loss would have improved physical function (PF) at 6 months vs. those who did not. METHODS Patients with stage 0-III breast cancer who completed local therapy and chemotherapy with BMI ≥ 25 kg/m2 were randomized to POWER-remote (telephone coaching; diet/activity tracking) or self-directed weight loss (booklet). Participants completed PROs at baseline, 6, and 12 months: PROMIS PF, pain, fatigue, anxiety, depression, sleep; FACT-endocrine symptoms; MOS-sexual function. Changes in PROs among those with ≥ 5% weight loss vs. those with < 5% were tested with multivariable mixed effect models, across randomized groups. RESULTS Of 94 women who completed PROs, 84 and 69 participants were evaluable at 6 and 12 months, respectively. Regardless of intervention, PF improved in those with ≥ 5% weight loss vs. those with < 5% at 6 months (4.4 vs. 0.3 points; p = 0.02) and 12 months (3.6 vs. 0 points; p = 0.04). While endocrine symptoms, fatigue, and anxiety improved at 6 months in those who lost ≥ 5%, differences were not significant vs. those who lost < 5%. There was no significant change within or between groups in sexual function, depression, or sleep. Findings at 12 months were similar, except pain improved in those losing ≥ 5%. CONCLUSIONS These results support the benefits of weight loss in overweight/obese breast cancer survivors. IMPLICATIONS FOR CANCER SURVIVORS Weight management in breast cancer survivors may improve PF.
Collapse
Affiliation(s)
- Jennifer Y Sheng
- Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. .,Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans St, Cancer Research Building 1, Room 142, Baltimore, MD, 21287, USA.
| | - Cesar A Santa-Maria
- Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Amanda L Blackford
- Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - David Lim
- Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Ashley Carpenter
- Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Karen L Smith
- Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Gary I Cohen
- Great Baltimore Medical Center, Baltimore, MD, USA
| | - Janelle Coughlin
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Lawrence J Appel
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.,Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Vered Stearns
- Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Claire Snyder
- Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.,Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
9
|
Walsh EM, Smith KL, Stearns V. Management of hormone receptor-positive, HER2-negative early breast cancer. Semin Oncol 2020; 47:187-200. [PMID: 32546323 PMCID: PMC7374796 DOI: 10.1053/j.seminoncol.2020.05.010] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2020] [Revised: 05/07/2020] [Accepted: 05/07/2020] [Indexed: 12/24/2022]
Abstract
The majority of breast cancers are diagnosed at an early stage and are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. Significant advances have been made in the management of early stage HR-positive, HER2-negative breast cancer, resulting in improved survival outcomes. In this review, we discuss important factors to consider in the management of this disease. In particular, we discuss the role of adjuvant endocrine therapy, specific endocrine therapy agents, the duration of adjuvant endocrine therapy, treatment-related side effects, and the role of genomic assays and other biomarkers when considering treatment recommendations for individuals with HR-positive, HER2-negative early breast cancer. Finally, we address emerging data to individualize therapeutic decision-making and provide future considerations.
Collapse
Affiliation(s)
- Elaine M Walsh
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD
| | - Karen L Smith
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD
| | - Vered Stearns
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD.
| |
Collapse
|
10
|
Brandão M, Coens C, Ignatiadis M. Patient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment? Ann Oncol 2019; 30:1677-1681. [PMID: 31613310 DOI: 10.1093/annonc/mdz404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- M Brandão
- Medical Oncology Department, Academic Trials Promoting Team, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium
| | - C Coens
- Department of Biostatistics, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium
| | - M Ignatiadis
- Medical Oncology Department, Academic Trials Promoting Team, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.
| |
Collapse
|
11
|
Life Quality Index Assessment in Breast Cancer Patients. Indian J Surg Oncol 2019; 10:476-482. [PMID: 31496595 DOI: 10.1007/s13193-019-00923-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2018] [Accepted: 04/05/2019] [Indexed: 10/27/2022] Open
Abstract
Breast cancer (BC) is the most common cancer in Indian females whether they are from urban or rural area. Quality of life after treatment in BC patients is a very vital issue as its assessment will guide the clinicians, hospital authorities, and administrators to take appropriate steps to improve the delivery of treatment and address the concern. Improvement in QOL should be one of the ultimate aims of treatment in BC. The aim of this review is to collect and examine literature available on QOL in breast cancer patients and define what type of issues or domains should be studied. Four factors including chemotherapy treatment received by the patient, associated comorbidities, social support to patients from family, friends, support groups, and income of family have been found to have a strong association with QOL in BC patients/survivors. QOL assessment should include an instrument which assesses physical health, social health, psychological health, and spiritual health. There are less studies having all above domains so more studies are required for better understanding of QOL issue in BC patients/survivors.
Collapse
|
12
|
Delaloge S, Cella D, Ye Y, Buyse M, Chan A, Barrios CH, Holmes FA, Mansi J, Iwata H, Ejlertsen B, Moy B, Chia SKL, Gnant M, Smichkoska S, Ciceniene A, Martinez N, Filipović S, Ben-Baruch NE, Joy AA, Langkjer ST, Senecal F, de Boer RH, Moran S, Yao B, Bryce R, Auerbach A, Fallowfield L, Martin M. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial. Ann Oncol 2019; 30:567-574. [PMID: 30689703 DOI: 10.1093/annonc/mdz016] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We report longitudinal health-related quality-of-life (HRQoL) data from the international, randomized, double-blind, placebo-controlled phase III ExteNET study, which demonstrated an invasive disease-free survival benefit of extended adjuvant therapy with neratinib over placebo in human epidermal growth factor receptor-2-positive early-stage breast cancer. PATIENTS AND METHODS Women (N = 2840) with early-stage HER2-positive breast cancer who had completed trastuzumab-based adjuvant therapy were randomly assigned to neratinib 240 mg/day or placebo for 12 months. HRQoL was an exploratory end point. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) and EuroQol 5-Dimensions (EQ-5D) questionnaires at baseline and months 1, 3, 6, 9, and 12. Changes from baseline were compared using analysis of covariance with no imputation for missing values. Sensitivity analyses used alternative methods. Changes in HRQoL scores were regarded as clinically meaningful if they exceeded previously reported important differences (IDs). RESULTS Of the 2840 patients (intention-to-treat population), 2407 patients were evaluable for FACT-B (neratinib, N = 1171; placebo, N = 1236) and 2427 patients for EQ-5D (neratinib, N = 1186; placebo, N = 1241). Questionnaire completion rates exceeded 85%. Neratinib was associated with a decrease in global HRQoL scores at month 1 compared with placebo (adjusted mean differences: FACT-B total, -2.9 points; EQ-5D index, -0.02), after which between-group differences diminished at later time-points. Except for the FACT-B physical well-being (PWB) subscale at month 1; all between-group differences were less than reported IDs. The FACT-B breast cancer-specific subscale showed small improvements with neratinib at months 3-9, but all were less than IDs. Sensitivity analyses exploring missing data did not change the results. CONCLUSIONS Extended adjuvant neratinib was associated with a transient, reversible decrease in HRQoL during the first month of treatment, possibly linked to treatment-related diarrhea. With the exception of the PWB subscale at month 1, all neratinib-related HRQoL changes did not reach clinically meaningful thresholds. ClinicalTrials.gov: NCT00878709.
Collapse
Affiliation(s)
- S Delaloge
- Department of Medicine, Institut Gustave Roussy, Villejuif, France.
| | - D Cella
- Department of Medical Social Sciences, Feinberg School of Medicine at Northwestern University, Chicago
| | - Y Ye
- Puma Biotechnology Inc, Los Angeles, USA
| | - M Buyse
- International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium
| | - A Chan
- Breast Cancer Research Centre-WA & Curtin University, Perth, Australia
| | - C H Barrios
- Oncology Research Unit, Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil
| | | | - J Mansi
- Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, London, UK
| | - H Iwata
- Department of Breast Oncology, Aichi Cancer Center, Chikusa-ku, Nagoya, Japan
| | - B Ejlertsen
- Department of Oncology, Rigshospitalet, Copenhagen, Denmark
| | - B Moy
- Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, USA
| | - S K L Chia
- Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
| | - M Gnant
- Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria
| | - S Smichkoska
- University Clinic for Radiotherapy and Oncology, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia
| | - A Ciceniene
- Oncology Institute of Vilnius University, Vilnius, Lithuania
| | - N Martinez
- Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - S Filipović
- Clinic of Oncology, Clinical Center Niš, Nis, Serbia
| | - N E Ben-Baruch
- Department of Oncology, Kaplan Medical Center, Rehovot, Israel
| | - A A Joy
- Cross Cancer Institute, Edmonton, Canada
| | - S T Langkjer
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - F Senecal
- Northwest Medical Specialties PLLC, Tacoma, USA
| | - R H de Boer
- Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, Australia
| | - S Moran
- Puma Biotechnology Inc, Los Angeles, USA
| | - B Yao
- Puma Biotechnology Inc, Los Angeles, USA
| | - R Bryce
- Puma Biotechnology Inc, Los Angeles, USA
| | - A Auerbach
- Puma Biotechnology Inc, Los Angeles, USA
| | - L Fallowfield
- Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Brighton, UK
| | - M Martin
- Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain
| |
Collapse
|
13
|
Park SH, Tish Knobf M, Jeon S. Endocrine Therapy-Related Symptoms and Quality of Life in Female Cancer Survivors in the Yale Fitness Intervention Trial. J Nurs Scholarsh 2019; 51:317-325. [PMID: 30874369 DOI: 10.1111/jnu.12471] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
PURPOSE The aim of the current study was to describe and compare endocrine therapy-related symptoms and quality of life in female cancer survivors taking aromatase inhibitors, tamoxifen, and no endocrine therapy, and to evaluate the effect of an exercise intervention on these symptoms and quality of life. DESIGN Randomized controlled trial. An aerobic resistance exercise intervention group was compared with a home-based exercise control group over 1 year. The exercise intervention was supervised for the first 6 months, followed by 6 unsupervised months. METHODS Perimenopausal and early postmenopausal female cancer survivors within 3 years of completing primary or adjuvant chemotherapy were selected. A total of 154 women were enrolled in the study. Type of endocrine or hormonal therapy was documented. Symptoms were measured by the Breast Cancer Prevention Trial Symptom Checklist and the Functional Assessment of Cancer Therapy-Endocrine Subscale. Quality of life was measured by the Functional Assessment of Cancer Therapy-General. Data were collected at baseline, and at 6 and 12 months. FINDINGS Participants generally had mild symptom distress. There was no difference in symptoms by endocrine therapy group or by exercise group. Participants taking aromatase inhibitors in the aerobic resistance exercise intervention group reported significant improvement in social, family, and functional well-being and better quality of life compared to those in the control group at 6 months but not at 12 months. CONCLUSIONS Findings were similar to those of previous large clinical trials in that no significant differences were found for endocrine therapy-related symptoms and quality of life by type of endocrine therapy taken. However, exercise may improve quality of life outcomes for women taking aromatase inhibitors. CLINICAL RELEVANCE Exercise has established efficacy for patient outcomes such as cardiovascular fitness, fatigue, weight management, and quality of life and may provide better quality of life for women who take aromatase inhibitors as adjuvant therapy.
Collapse
Affiliation(s)
- So-Hyun Park
- Alpha Zeta, Assistant Professor, Hunter Bellevue School of Nursing, City University of New York, New York, NY,, USA
| | - M Tish Knobf
- Delta Mu , Professor of Nursing and Acute Care/Health Systems Division Chair, Yale University School of Nursing, Orange, CT,, USA
| | - Sangchoon Jeon
- Research Scientist in Nursing, Yale University School of Nursing, Orange, CT,, USA
| |
Collapse
|
14
|
Characteristics of adverse events of endocrine therapies among older patients with breast cancer. Support Care Cancer 2019; 27:3813-3822. [DOI: 10.1007/s00520-019-04674-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Accepted: 09/26/2018] [Indexed: 11/26/2022]
|
15
|
Raghavendra A, Sinha AK, Valle-Goffin J, Shen Y, Tripathy D, Barcenas CH. Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors. Clin Breast Cancer 2018; 18:e7-e13. [PMID: 29239836 PMCID: PMC5937690 DOI: 10.1016/j.clbc.2017.11.006] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Revised: 10/26/2017] [Accepted: 11/03/2017] [Indexed: 12/14/2022]
Abstract
BACKGROUND Weight gain is a negative prognostic factor in breast cancer (BC) patients. The risk factors for weight gain during adjuvant endocrine therapy (ET) and the extent to which such weight gain is associated with disease recurrence remain unclear. PATIENTS AND METHODS We retrospectively identified a cohort of women with a diagnosis of stage I-III, hormone receptor-positive, human epidermal growth factor receptor 2-negative BC from January 1997 to August 2008, who had received initial treatment at the MD Anderson Cancer Center, had completed 5 years of ET, and had remained free of locoregional or distant relapse or contralateral BC for ≥ 5 years after diagnosis. The weight change at the end of 5 years of ET was measured as the percentage of the change in weight from the start of ET, with a weight gain of > 5% considered clinically significant. Multivariable logistic regression and Cox proportional hazards models were used to assess the determinants of such weight gain and the risk of recurrence after 5 years. RESULTS Of 1282 long-term BC survivors, 432 (33.7%) had a weight gain of > 5% after 5 years of ET. Women who were premenopausal at diagnosis were 1.40 times more likely than women who were postmenopausal at diagnosis to have a weight gain of > 5%. Asian women had the lowest risk of gaining weight. The recurrence risks of patients who had gained weight and those who had not were not significantly different. CONCLUSION Premenopausal BC patients had an increased risk of weight gain after 5 years of ET; however, BC patients with a weight gain of > 5% did not have an increased risk of disease recurrence.
Collapse
Affiliation(s)
- Akshara Raghavendra
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Arup K Sinha
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Biostatistics, The University of Texas School of Public Health, Houston, TX
| | | | - Yu Shen
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Debu Tripathy
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Carlos H Barcenas
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
| |
Collapse
|
16
|
Sousa M, Peate M, Lewis C, Jarvis S, Willis A, Hickey M, Friedlander M. Exploring knowledge, attitudes and experience of genitourinary symptoms in women with early breast cancer on adjuvant endocrine therapy. Eur J Cancer Care (Engl) 2018; 27:e12820. [PMID: 29337398 DOI: 10.1111/ecc.12820] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/17/2017] [Indexed: 11/29/2022]
Abstract
Clinical trials of adjuvant endocrine therapy in women with early breast cancer have consistently reported that genitourinary symptoms are common. However, little is known about women's experiences of genitourinary symptoms, their views about the symptoms and how they impact on their lives. The aim of this study was to explore knowledge, attitudes and experiences of genitourinary symptoms among women receiving adjuvant endocrine therapy for early breast cancer. Thirty-two semi-structured interviews were conducted and subjected to a rigorous qualitative analysis. Genitourinary symptoms were commonly reported to negatively impact on personal, social and physical activities, were often attributed to anxiety and stress and were a source of embarrassment. Women also commented on the limited information available or provided regarding the potential genitourinary adverse effects of adjuvant endocrine therapy. There was a general lack of awareness that their symptoms could be associated with or exacerbated by adjuvant endocrine therapy. Women indicated a preference to receive information and advice about potential management options from either their general practitioner or specialist. These findings underscore the importance of improving communication and increasing awareness among both clinicians and patients about the potential impact of adjuvant endocrine therapy on genitourinary symptoms.
Collapse
Affiliation(s)
- M Sousa
- Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.,School of Nursing and Midwifery, Centre for Applied Nursing Research, South Western Sydney Local Health District, Ingham Institute for Applied Medical Research, Western Sydney University, Sydney, NSW, Australia
| | - M Peate
- Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC, Australia.,The Royal Women's Hospital, Parkville, VIC, Australia
| | - C Lewis
- Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.,Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia
| | - S Jarvis
- Pelvic Floor Physiotherapy, Women's Health & Research Institute of Australia, Sydney, NSW, Australia
| | - A Willis
- Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.,Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia
| | - M Hickey
- Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC, Australia.,The Royal Women's Hospital, Parkville, VIC, Australia
| | - M Friedlander
- Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.,Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia
| |
Collapse
|
17
|
Laroche F, Perrot S, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Chauvenet L, Bouhassira D, Coste J. Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study. PLoS One 2017; 12:e0187165. [PMID: 29117210 PMCID: PMC5678681 DOI: 10.1371/journal.pone.0187165] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2017] [Accepted: 10/14/2017] [Indexed: 12/02/2022] Open
Abstract
Women with hormone-dependent breast cancer are treated with aromatase inhibitors (AI) to slow disease progression by decreasing estrogen levels. However, AI have adverse effects, including pain, with potentially serious impact on quality of life (QOL) and treatment compliance. We evaluated quality of life during the first year of AI treatment, focusing particularly on the impact of pain. In a multicenter cohort study of 135 women with early-stage breast cancer, free of pain at the initiation of AI treatment, quality of life (by the EORTC QLQ-BR23), somatic and psychic symptoms, psychological characters, temperament and coping strategies were assessed at baseline and at each follow-up visit (1, 3, 6 and 12 months). The impact of treatment-induced pain on quality of life during follow-up was determined with repeated-measures regression models. These models were constructed to assess the effects of pain and pain type on quality of life during follow-up, taking into account predictors associated with quality of life at baseline. Prior ganglion resection, taxane treatment and chemotherapy, a high amplification score on the pain catastrophizing scale, and a high harm avoidance score on the personality questionnaire were associated with a significantly lower baseline QOL. Fifty-seven percent of women developed pain of five different types: upper or lower limb joint pain, diffuse pain, neuropathic pain, tendon pain and mixed pain. A significant decrease in QOL was noted in the women with pain, particularly for body image, sexual functioning and future perspectives. Moreover, the impact of pain on QOL depended on the type of pain experienced. In conclusion, women treated with aromatase inhibitors display changes in quality of life and the degree of change in quality of life depends mostly on the type of pain experienced. Oncologists and patients should be aware of painful adverse effects of AI and encouraged to provide or receive earlier and more appropriate management of these effects.
Collapse
Affiliation(s)
- Françoise Laroche
- Pain Clinic, Saint Antoine Hospital, Paris, France
- INSERM U 987 and U 938, Paris, France
| | - Serge Perrot
- INSERM U 987 and U 938, Paris, France
- Pain Clinic and Internal Medicine Department, Hôtel Dieu Hospital, Paris, France
| | - Terkia Medkour
- Pain Clinic and Internal Medicine Department, Hôtel Dieu Hospital, Paris, France
| | | | | | | | | | | | | | | | - Joël Coste
- Biostatistics and Epidemiology Unit, Hôtel Dieu Hospital, Paris, France
- * E-mail:
| |
Collapse
|
18
|
Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain. Breast Cancer Res Treat 2017; 167:709-718. [PMID: 29101597 DOI: 10.1007/s10549-017-4559-z] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Accepted: 10/27/2017] [Indexed: 10/18/2022]
Abstract
PURPOSE Aromatase inhibitor (AI)-induced joint symptoms negatively impact drug adherence and quality of life in breast cancer survivors. Mechanisms underlying symptoms may include inflammation. It is hypothesized that n - 3 polyunsaturated fatty acids (PUFAs) have anti-inflammatory properties and may reduce symptoms. METHODS We conducted a randomized, double-blind, placebo-controlled study comparing 4.3 g/day n - 3 PUFA supplements vs placebo for 24 weeks in postmenopausal breast cancer patients starting adjuvant AIs. Primary endpoints were adherence and tolerability; secondary outcomes included inflammatory cytokines and symptoms assessed by the Brief Pain Inventory short form (BPI-SF) and Functional Assessment of Cancer Treatment-Endocrine Symptoms (FACT-ES) at 0, 12, and 24 weeks. RESULTS Forty-four women were randomized, of which 35 completed the study. Adherence was ≥ 88% based on these 35 patients with pill counts as well as change in red blood cell (RBC) n - 3 PUFAs. Common toxicities included grade 1 flatulence (55% of both groups) and belching (45% of n - 3 group). Mean pain severity scores (BPI-SF) did not change significantly by time or treatment arm. Quality of life, based on FACT-ES scores, significantly decreased within placebo (p = 0.04), but not the n - 3 group (p = 0.58), with a trend toward between-group differences (p = 0.06) at 12 weeks, but no significant differences at 24 weeks. RBC n - 3 levels were strongly positively correlated with FACT-ES at 12 weeks, but attenuated at 24 weeks. CONCLUSION High-dose n - 3 PUFA supplementation is feasible and well tolerated when administered with AIs. Additional studies are needed to evaluate efficacy in prevention of joint symptoms.
Collapse
|
19
|
Mougalian SS, Epstein LN, Jhaveri AP, Han G, Abu-Khalaf M, Hofstatter EW, DiGiovanna MP, Silber AL, Adelson K, Pusztai L, Gross CP. Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer. JCO Clin Cancer Inform 2017; 1:1-10. [DOI: 10.1200/cci.17.00015] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Introduction Up to 40% of patients with breast cancer may not adhere to adjuvant endocrine therapy. Therapy-related adverse effects (AEs) are important contributors to nonadherence. We developed a bidirectional text-message application, BETA-Text, that simultaneously tracks adherence, records symptoms, and alerts the clinical team. Patients and Methods We piloted our intervention in 100 patients. The intervention consisted of text messages to which patients responded for 3 months: daily, evaluating adherence; weekly, evaluating medication-related AEs; and monthly, regarding barriers to adherence. Concerning responses prompted a telephone call from a clinic nurse. The primary objective was to assess patient acceptance of this intervention using self-reported surveys. To compare participants with the general population at our institution, we assessed 100 consecutively treated patients as historical controls using medical record review. Results We approached 141 consecutive patients, 100 (71%) of whom agreed to participate and 89 of whom completed the intervention. A majority of patients reported that the intervention was easy to use (98%) and helpful in taking their medication (96%). Four patients discontinued therapy before 3 months, and 93% of patients who continued therapy took ≥ 80% of their medication. The frequency of AEs reported by participants via text was higher than that reported in clinical trials: hot flashes (72%), arthralgias (53%), and vaginal symptoms (35%). Approximately 39% of patients reported one or more severe AE that prompted an alert to the provider team to call the patient. Conclusion A daily bidirectional text-messaging system can monitor adherence and identify AEs and other barriers to adherence in real time without inconveniencing patients. AEs of endocrine therapy, as detected using this texting approach, are more prevalent than reported in clinical trials.
Collapse
Affiliation(s)
- Sarah S. Mougalian
- Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - Lianne N. Epstein
- Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - Ami P. Jhaveri
- Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - Gang Han
- Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - Maysa Abu-Khalaf
- Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - Erin W. Hofstatter
- Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - Michael P. DiGiovanna
- Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - Andrea L.M. Silber
- Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - Kerin Adelson
- Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - Lajos Pusztai
- Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| | - Cary P. Gross
- Sarah S. Mougalian, Lianne N. Epstein, Erin W. Hofstatter, Michael P. DiGiovanna, Andrea L.M. Silber, Kerin Adelson, Lajos Pusztai, and Cary P. Gross, Yale Cancer Center, Yale University; Sarah S. Mougalian, Kerin Adelson, and Cary P. Gross, Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, Yale University, New Haven, CT; Ami P. Jhaveri, Lancaster General Health, Penn Medicine, Lancaster; Maysa Abu-Khalaf, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA
| |
Collapse
|
20
|
Khan QJ, Kimler BF, Reddy PS, Sharma P, Klemp JR, Nydegger JL, Yeh HW, Fabian CJ. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial. Breast Cancer Res Treat 2017; 166:491-500. [PMID: 28770449 DOI: 10.1007/s10549-017-4429-8] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Accepted: 07/28/2017] [Indexed: 02/07/2023]
Abstract
PURPOSE Aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) frequently occur in women being treated for breast cancer. Prior studies suggest high prevalence of vitamin D deficiency in breast cancer patients with musculoskeletal (MS) pain. We conducted a randomized, placebo-controlled trial to determine if 30,000 IU vitamin D3 per week (VitD3) would prevent worsening of AIMSS in women starting adjuvant letrozole for breast cancer. METHODS Women with stage I-III breast cancer starting adjuvant letrozole and 25(OH)D level ≤40 ng/ml were eligible. All subjects received standard daily supplement of 1200 mg calcium and 600 IU vitamin D3 and were randomized to 30,000 IU oral VitD3/week or placebo. Pain, disability, fatigue, quality of life, 25(OH)D levels, and hand grip strength were assessed at baseline, 12, and 24 weeks. The primary endpoint was incidence of an AIMSS event. RESULTS Median age of the 160 subjects (80/arm) was 61. Median 25OHD (ng/ml) was 25 at baseline, 32 at 12 weeks, and 31 at 24 weeks in the placebo arm and 22, 53, and 57 in the VitD3 arm. There were no serious adverse events. At week 24, 51% of women assigned to placebo had a protocol defined AIMSS event (worsening of joint pain using a categorical pain intensity scale (CPIS), disability from joint pain using HAQ-II, or discontinuation of letrozole due to MS symptoms) vs. 37% of women assigned to VitD3 (p = 0.069). When the brief pain inventory (BPI) was used instead of CPIS, the difference was statistically significant: 56 vs. 39% (p = 0.024). CONCLUSIONS Although 30,000 IU/week of oral vitamin D3 is safe and effective in achieving adequate vitamin D levels, it was not associated with a decrease in AIMSS events based on the primary endpoint. Post-hoc analysis using a different tool suggests potential benefit of vitamin D3 in reducing AIMSS.
Collapse
Affiliation(s)
- Qamar J Khan
- Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
| | - Bruce F Kimler
- Department of Radiation Oncology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, 66160-7321, USA.
| | | | - Priyanka Sharma
- Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
| | - Jennifer R Klemp
- Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
| | - Jennifer L Nydegger
- Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
| | - Hung-Wen Yeh
- Laureate Institute for Brain Research, Tulsa, OK, USA
| | - Carol J Fabian
- Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
| |
Collapse
|
21
|
Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC. Long-Term Follow-Up of the Intergroup Exemestane Study. J Clin Oncol 2017; 35:2507-2514. [PMID: 28467729 PMCID: PMC6175047 DOI: 10.1200/jco.2016.70.5640] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Purpose The Intergroup Exemestane Study, an investigator-led study of 4,724 postmenopausal patients with early breast cancer (clinical trial information: ISRCTN11883920), has previously demonstrated that a switch from adjuvant endocrine therapy after 2 to 3 years of tamoxifen to exemestane was associated with clinically relevant improvements in efficacy. Here, we report the final efficacy analyses of this cohort. Patients and Methods Patients who remained disease free after 2 to 3 years of adjuvant tamoxifen were randomly assigned to continue tamoxifen or switch to exemestane to complete a total of 5 years of adjuvant endocrine therapy. Given the large number of non-breast cancer-related deaths now reported, breast cancer-free survival (BCFS), with censorship of intercurrent deaths, was the primary survival end point of interest. Analyses focus on patients with estrogen receptor-positive or unknown tumors (n = 4,599). Results At the time of the data snapshot, median follow-up was 120 months. In the population that was estrogen receptor positive or had unknown estrogen receptor status, 1,111 BCFS events were observed with 508 (22.1%) of 2,294 patients in the exemestane group and 603 (26.2%) of 2,305 patients in the tamoxifen group. The data corresponded to an absolute difference (between exemestane and tamoxifen) at 10 years of 4.0% (95% CI, 1.2% to 6.7%), and the hazard ratio (HR) of 0.81 (95% CI, 0.72 to 0.92) favored exemestane. This difference remained in multivariable analysis that was adjusted for nodal status, prior use of hormone replacement therapy, and prior chemotherapy (HR, 0.80; 95% CI, 0.71 to 0.90; P < .001). A modest improvement in overall survival was seen with exemestane; the absolute difference (between exemestane and tamoxifen) at 10 years in the population that was estrogen receptor positive or had unknown estrogen receptor status was 2.1% (95% CI, -0.5% to 4.6%), and the HR was 0.89 (95% CI, 0.78 to 1.01; P = .08). For the intention-to-treat population, the absolute difference was 1.6% (95% CI, -0.9% to 4.1%); the HR was 0.91 (95% CI, 0.80 to 1.03, P = .15). No statistically significant difference was observed in the proportion of patients who reported a fracture event in the post-treatment period. Conclusion The Intergroup Exemestane Study and contemporaneous studies have established that a strategy of switching to an aromatase inhibitor after 2 to 3 years of tamoxifen can lead to sustained benefits in terms of reduction of disease recurrence and breast cancer mortality.
Collapse
Affiliation(s)
- James P Morden
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Isabel Alvarez
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Gianfilippo Bertelli
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Alan S Coates
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Robert Coleman
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Lesley Fallowfield
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Jacek Jassem
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Stephen Jones
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Lucy Kilburn
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Per E Lønning
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Olaf Ortmann
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Claire Snowdon
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Cornelis van de Velde
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Jørn Andersen
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Lucia Del Mastro
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - David Dodwell
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Stig Holmberg
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Hanna Nicholas
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Robert Paridaens
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - Judith M Bliss
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| | - R Charles Coombes
- James P. Morden, Lucy Kilburn, Claire Snowdon, and Judith M. Bliss, The Institute of Cancer Research; Hanna Nicholas, Cancer Research UK; R. Charles Coombes, Imperial College London, London; Gianfilippo Bertelli, Singleton Hospital, Swansea; Robert Coleman, Weston Park Hospital, Sheffield; Lesley Fallowfield, University of Sussex, Brighton; David Dodwell, St James Hospital, Leeds, United Kingdom; Isabel Alvarez, Hospital Donostia, GEICAM Spanish Breast Cancer Group, San Sebastian, Spain; Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Stephen Jones, US Oncology Research, The Woodlands, TX; Per E. Lønning, University of Bergen and Haukeland University Hospital, Bergen, Norway; Olaf Ortmann, University Medical Center Regensburg, Regensburg, Germany; Cornelis van de Velde, Leiden University Medical Centre, Leiden, the Netherlands; Jørn Andersen, Aarhus University Hospital, Aarhus, Denmark; Lucia Del Mastro, IRCCS Azienda Ospedaliera Universitaria San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Stig Holmberg, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden; and Robert Paridaens, Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium
| |
Collapse
|
22
|
Landi SN, Doll KM, Bensen JT, Hendrix L, Anders CK, Wu JM, Nichols HB. Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis. Cancer Causes Control 2016; 27:1325-1332. [PMID: 27680018 PMCID: PMC5835969 DOI: 10.1007/s10552-016-0810-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Accepted: 09/24/2016] [Indexed: 11/28/2022]
Abstract
PURPOSE Endocrine therapy for breast cancer can exacerbate menopausal symptoms. The association between endocrine therapy and common pelvic floor disorders including urinary incontinence has rarely been evaluated. We examined urogenital and sexual side effects among women with a breast cancer diagnosis, comparing endocrine therapy users to nonusers. METHODS Urogenital and sexual symptoms were self-reported during the enrollment interview within the University of North Carolina Cancer Survivorship Cohort. Tumor characteristics and endocrine therapy use were collected from medical and prescription records. We calculated multivariable prevalence ratios (PR) and 95 % confidence intervals (CI) for the association of endocrine therapy (versus no endocrine therapy) and urinary incontinence, overall and by therapy type (tamoxifen or aromatase inhibitors). PROMIS Sexual Function and Satisfaction domain scores were compared across endocrine therapy groups. RESULTS Among the 548 women with a breast cancer diagnosis, 49 % received endocrine therapy. Overall, 18 % of women reported urinary incontinence symptoms. We observed no association between urinary incontinence and endocrine therapy use overall (PR = 0.97; 95 % CI 0.67, 1.43), tamoxifen (PR = 1.20; 95 % CI 0.74, 1.96), or aromatase inhibitors (PR = 0.89; 95 % CI 0.55, 1.42), compared to no use. Approximately 55 % of women were sexually active. Sexual function scores did not vary according to endocrine therapy use, although urinary incontinence was associated with lower satisfaction scores (p = 0.05). CONCLUSIONS Our findings demonstrate a high prevalence of urinary incontinence after breast cancer diagnosis similar to the overall prevalence in older U.S. women, and this did not vary strongly according to use of endocrine therapy.
Collapse
Affiliation(s)
- Suzanne N Landi
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 135 Dauer Drive, 2101 McGavran-Greenberg Hall, Chapel Hill, NC, 27599-7435, USA.
| | - Kemi M Doll
- Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 135 Dauer Drive, 170 Rosenau Hall, Chapel Hill, NC, 27599-7400, USA
- Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC, 27599-7295, USA
| | - Jeannette T Bensen
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 135 Dauer Drive, 2101 McGavran-Greenberg Hall, Chapel Hill, NC, 27599-7435, USA
- Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC, 27599-7295, USA
| | - Laura Hendrix
- Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC, 27599-7295, USA
| | - Carey K Anders
- Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina at Chapel Hill, 450 West Drive, Chapel Hill, NC, 27599-7295, USA
| | - Jennifer M Wu
- Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, 3032 Old Clinic Building, Chapel Hill, NC, 27599-7570, USA
| | - Hazel B Nichols
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 135 Dauer Drive, 2101 McGavran-Greenberg Hall, Chapel Hill, NC, 27599-7435, USA
| |
Collapse
|
23
|
Body mass index and menopausal disorders during menopause affect vasomotor symptoms of postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. Breast Cancer 2016; 24:528-534. [PMID: 27730528 DOI: 10.1007/s12282-016-0735-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2016] [Accepted: 09/29/2016] [Indexed: 10/20/2022]
Abstract
BACKGROUND Adverse events related to endocrine therapies have a major impact not only on patients' quality of life but also on treatment discontinuation. Although vasomotor symptoms induced by aromatase inhibitors are frequently recognized, risk factors, especially for Japanese women, are not well reported. To identify risk factors for vasomotor symptoms of Japanese breast cancer patients treated with adjuvant anastrozole, we conducted a prospective cohort study based on patient-reported outcomes (PROs). PATIENTS AND METHODS For this prospective cohort study (SAVS-JP, UMIN000002455), 391 postmenopausal Japanese estrogen receptor-positive breast cancer patients who were treated with adjuvant anastrozole were recruited from 28 centers. The PRO assessment was obtained from a self-reported questionnaire at baseline, 3, 6, 9 and 12 months between August 2009 and April 2012. Vasomotor symptoms, comprising hot flashes, night sweats, and cold sweats, were categorized into four grades (none, Grade 1: mild, Grade 2: moderate, Grade 3: severe). Pre-existing symptoms were only included if they had become worse than at baseline. RESULTS Hot flashes, night sweats, and cold sweats at baseline were reported by 20.5, 15.1, and 8.2 % of the patients, respectively, and new appearance or worsening of symptoms in comparison with baseline by 38.4, 29.3, and 28.7 %, respectively. About 80 % of newly occurring symptoms were Grade 1, and less than 5 % were Grade 3. Vasomotor symptoms were reported by 201 out of 362 patients (55.5 %) during the first year and the mean time to onset was 5.6 months. Patients with vasomotor symptoms were significantly younger (mean 62.8 years, range 38-86 vs 64.7 years, range 37-84; p = 0.02), had higher body mass index (BMI) (23.4 kg/m2, range 15.8-39.9 vs 22.4 kg/m2, range 15.8-34.9; p = 0.01), had vasomotor symptoms sooner after menopause (12.4 years, range 0-51 vs 15.1 years, range 1-37; p = 0.002), and had more menopausal disorders during menopause (63.3 vs 36.7 %; p = 0.002). Multivariate analysis showed that BMI [odds ratio (OR) 1.09 per unit of increase, 95 % confidence interval (CI) 1.02-1.16; p = 0.009] and experiencing menopausal disorders (OR 2.11, 95 % CI 1.35-3.30; p = 0.001) were significantly associated with vasomotor symptoms. CONCLUSION High BMI and experiencing menopausal disorders at menopause were found to be significantly associated with the occurrence of vasomotor symptoms. These findings are expected to prove useful for the management of postmenopausal Japanese women treated with aromatase inhibitors.
Collapse
|
24
|
Borrie AE, Kim RB. Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers. Expert Opin Drug Metab Toxicol 2016; 13:149-156. [PMID: 27635473 DOI: 10.1080/17425255.2017.1234605] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
INTRODUCTION Aromatase inhibitors (AIs) are routinely used for the adjuvant treatment of women with hormone receptor-positive early breast cancer. AIs are widely prescribed in the postmenopausal setting, as they are effective at preventing recurrence. However, their use is complicated by significant adverse effects, particularly arthralgia, noted in up to 50% of treated patients, and thereby affects quality of life and AI compliance. The mechanism by which AIs cause arthralgia is largely unknown, although there is a growing body of literature which suggests that there may be multiple intersecting mechanisms. Areas covered: This review describes the evidence for the mechanistic basis of AI arthralgia as well as potential pathways that could contribute to the development of AI associated arthralgia. Expert opinion: Interplay of multiple factors, such as interpatient variability in AI metabolism, possibly related to pharmacogenetic factors, the sudden decline of estrogen synthesis, vitamin D status, as well as upregulation of cytokines and inflammation pathways may precipitate or exacerbate muscle and joint pain are linked during AI therapy. However, much more research is needed in this area given the frequency and severity of AI-associated arthralgia.
Collapse
Affiliation(s)
- Adrienne E Borrie
- a Division of Clinical Pharmacology, Department of Medicine , Western University , London , ON , Canada.,b Department of Physiology and Pharmacology , Western University , London , ON , Canada
| | - Richard B Kim
- a Division of Clinical Pharmacology, Department of Medicine , Western University , London , ON , Canada.,b Department of Physiology and Pharmacology , Western University , London , ON , Canada
| |
Collapse
|
25
|
Gradishar WJ. Treatment challenges for community oncologists treating postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Cancer Manag Res 2016; 8:85-94. [PMID: 27468248 PMCID: PMC4946864 DOI: 10.2147/cmar.s98249] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Community-based oncologists are faced with challenges and opportunities when delivering quality patient care, including high patient volumes and diminished resources; however, there may be the potential to deliver increased patient education and subsequently improve outcomes. This review discusses the treatment of postmenopausal women with endocrine-resistant, hormone receptor-positive, human epidermal growth factor receptor 2- negative advanced breast cancer in order to illustrate considerations in the provision of pertinent quality education in the treatment of these patients and the management of therapy-related adverse events. An overview of endocrine-resistant breast cancer and subsequent treatment challenges is also provided. Approved treatment options for endocrine-resistant breast cancer include hormonal therapies and mammalian target of rapamycin inhibitors. Compounds under clinical investigation are also discussed.
Collapse
Affiliation(s)
- William J Gradishar
- Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| |
Collapse
|
26
|
Nyrop KA, Williams GR, Muss HB, Shachar SS. Weight gain during adjuvant endocrine treatment for early-stage breast cancer: What is the evidence? Breast Cancer Res Treat 2016; 158:203-17. [PMID: 27342454 DOI: 10.1007/s10549-016-3874-0] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Accepted: 06/17/2016] [Indexed: 12/14/2022]
Abstract
Most breast cancer (BC) tumors are early stage and hormone receptor positive, where treatment generally includes adjuvant endocrine treatment (ET). Oncology providers and women about to start ET want to know about side effects, including potential weight gain. The aim of this study was a literature review to identify the independent effect of ET on post-diagnosis weight gain. Weight gain is of concern with regard to potential associations with BC recurrence, mortality, and quality of life in survivorship. We conducted a targeted review of the literature. Thirty-eight studies met our inclusion criteria. Patient-reported weight gain ranged widely from 18 to 52 % of patients in Year 1 and from 7 to 55 % in Year 5. Some studies reported categories of weight change: lost weight (9-17 %), stable weight (47-64 %), and gained weight (27-36 %). Most studies comparing ET with placebo or tamoxifen with AI reported no significant difference between the two groups. Wide-ranging and inconsistent results point to the need for further research to clarify annual weight change (loss, gain, stability) from BC diagnosis through 5 years of ET and beyond. There is also a need to explore weight change by type of ET and to explore risk factors for weight gain in women on ET, including tumor type, sociodemographic characteristics, and health behaviors. More specific information is needed to identify high-risk BC patients who could be targeted for weight management interventions.
Collapse
Affiliation(s)
- K A Nyrop
- School of Medicine, University of North Carolina at Chapel Hill, Campus Box 7305, Chapel Hill, NC, 27599-7305, USA.
| | - G R Williams
- School of Medicine, University of North Carolina at Chapel Hill, Campus Box 7305, Chapel Hill, NC, 27599-7305, USA
| | - H B Muss
- School of Medicine, University of North Carolina at Chapel Hill, Campus Box 7305, Chapel Hill, NC, 27599-7305, USA
| | - S S Shachar
- School of Medicine, University of North Carolina at Chapel Hill, Haifa, Israel
| |
Collapse
|
27
|
Cao A, Zhang J, Liu X, Wu W, Liu Y, Fan Z, Zhang A, Zhou T, Fu P, Wang S, Ouyang Q, Tang J, Jiang H, Zhang X, Pang D, He J, Shi L, Wang X, Sheng Y, Mao D, Shao Z. Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study. Health Qual Life Outcomes 2016; 14:51. [PMID: 27009092 PMCID: PMC4806477 DOI: 10.1186/s12955-016-0446-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Accepted: 03/09/2016] [Indexed: 11/26/2022] Open
Abstract
Background Estimating quality of life (QoL) in patients with breast cancer is of importance in assessing treatment outcomes. Adjuvant endocrine therapy is widely used for hormone receptor-positive (HR+) early-stage breast cancer (EBC), and evidence suggests that aromatase inhibitors (AIs) may improve QoL for these patients. This study evaluated QoL in postmenopausal Chinese patients with HR+ EBC taking AIs. Methods This was a prospective, multicenter, and observational study that had no intent to intervene in the current treatment of recruited patients. Eligible patients were recruited within 7 days of beginning adjuvant treatment with AIs. The Functional Assessment of Cancer Therapy-Breast (FACT-B) scale was used to evaluate the patients’ QoL. Data were collected at baseline and at 6, 12, 18, and 24 months. Results From June 2010 to October 2013, a total of 494 patients with HR+ EBC were recruited from 21 centers. There was a 7.51-point increase in the patients’ mean FACT-B trial outcome index (TOI), from 90.69 at baseline to 98.72 at 24 months (P < .0001). The mean TOI scores at baseline, 6, 12, and 18 months were 90.69, 94.36, 97.71, and 96.75, respectively (P < .0001, for all). The mean (FACT-B) emotional well-being subscale scores at baseline, 6, 12, 18, and 24 months were 16.32, 16.55, 17.34 (P < .0001), 17.47 (P < .0001), and 17.85 (P < .0001), respectively, and social well-being scores were 18.61, 19.14 (P < .04), 19.35 (P < .008), 18.32, and 18.40, respectively. In the mixed model, baseline TOI, clinical visits, prior chemotherapies, age group, and axillary lymph-node dissection presented statistically significant effects on the change of FACT-B TOI and FACT-B SWB, whereas only baseline TOI, clinical visits, and prior chemotherapies presented statistically significant effects on the change of FACT-B EWB. FACT-B TOI, being the most pertinent and precise indicator of patient-reported QoL, demonstrated significant changes reflecting clinical benefit of adjuvant AIs endocrine therapy in the QoL of HR + EBC patients. Conclusions The study demonstrated significant improvements in the long-term QoL of postmenopausal Chinese patients with HR+ EBC at 6, 12, 18, and 24 months after starting treatment with AIs. The current study indicates improved long-term QoL with AI adjuvant treatment, which will aid clinicians in optimizing treatment to yield effective healthcare outcomes. Trial registration Clinicaltrials.gov NCT01144572
Collapse
Affiliation(s)
- Ayong Cao
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Xuhui District, Shanghai, 200032, China
| | - Jin Zhang
- Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China
| | - Xiaoan Liu
- Department of Breast Surgery, Jiangsu Province Hospital, Nanjing, China
| | - Weizhu Wu
- Department of Oncology Surgery, Ningbo Medical Treatment Center Lihuili Hospital, Ningbo, 315000, China
| | - Yinhua Liu
- Breast Disease Center, Peking University First Hospital, Beijing, 100034, China
| | - Zhimin Fan
- Department of Breast Surgery, First Hospital of Jilin University, Changchun, 130021, China
| | - Anqin Zhang
- Breast Disease Center, Guangdong Women and Children's Hospital and Health Institute, Guangzhou, 510010, China
| | - Tianning Zhou
- Department of Breast Disease, Yunnan Tumor Hospital, Kunming, 650118, China
| | - Peifen Fu
- Breast Disease Center, First Affiliated Hospital of Medicine College of Zhejiang University, Hangzhou, 310006, China
| | - Shu Wang
- Breast Disease Center, Peking University People's Hospital, Beijing, 100044, China
| | - Quchang Ouyang
- Medical Oncology Center, Hunan Tumor Hospital, Changsha, 410000, China
| | - Jinhai Tang
- Department of General Surgery, Jiangsu Cancer Hospital, Nanjing, 210009, China
| | - Hongchuan Jiang
- Department of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China
| | - Xiaohua Zhang
- Department of Oncology Surgery, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, China
| | - Da Pang
- Department of Breast Surgery, The Tumor Hospital of Harbin Medical University, Harbin, 150040, China
| | - Jianjun He
- Department of Surgical Oncology, The First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, 710000, China
| | - Linxiang Shi
- Department of Breast and Thyroid Surgery, Shanghai Tenth People's Hospital, Shanghai, 200072, China
| | - Xianming Wang
- Department of Breast and Thyroid Surgery, Shenzhen Second Hospital, Shenzhen, 518000, China
| | - Yuan Sheng
- Department of Breast Surgery, Shanghai Changhai Hospital, Shanghai, 200433, China
| | - Dahua Mao
- Department of Breast Surgery, The Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou, 550004, China
| | - Zhimin Shao
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Xuhui District, Shanghai, 200032, China.
| |
Collapse
|
28
|
Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL. Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist 2016; 21:539-46. [PMID: 27009936 PMCID: PMC4861358 DOI: 10.1634/theoncologist.2015-0349] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Accepted: 11/27/2015] [Indexed: 12/03/2022] Open
Abstract
In the prospective Exemestane and Letrozole Pharmacogenetics trial of adjuvant aromatase inhibitor (AI) therapy for early-stage breast cancer, worsening of multiple treatment-related symptoms during AI therapy predicted AI early discontinuation. If these findings are confirmed in independent trials, early detection of changes in PRO measures could be used clinically to target interventions in patients at high risk for early discontinuation. Background. Early discontinuation of aromatase inhibitors (AIs) is common and leads to poor outcomes but is challenging to predict. In the Exemestane and Letrozole Pharmacogenetics trial, a high rate of early discontinuation due to intolerance was observed. We hypothesized that early changes in patient-reported outcomes (PROs) predict AI discontinuation and that biochemical factors are associated with changes in PROs. Patients and Methods. Postmenopausal women with early-stage breast cancer enrolled in a prospective randomized trial of exemestane versus letrozole completed questionnaires at baseline and serially over 24 months to assess overall quality of life (EuroQOL Visual Analog Scale [VAS]); mood; and multiple symptoms, including a musculoskeletal symptom cluster. A joint mixed-effects/survival model was used to estimate the effect of the change in PROs on AI discontinuation. Associations between biochemical factors and change in PROs were examined. Results. A total of 490 patients were analyzed. Worsening of EuroQOL VAS and the musculoskeletal cluster were associated with the highest risk for early discontinuation (hazard ratio [HR], 2.77 [95% confidence interval (CI), 2.72–2.81; p = .015]; HR, 4.39 [95% CI, 2.40–8.02; p < .0001], respectively). Pharmacokinetics and estrogen metabolism were not consistently associated with change in PRO measures. No clinically significant differences in any PRO between AIs were observed. Conclusion. Changes in PROs early during AI therapy were associated with treatment discontinuation. Identification of these changes could be used to target interventions in patients at high risk for early discontinuation. Implications for Practice: Early changes in patient-reported outcomes (PROs) can predict nonpersistence to aromatase inhibitor therapy. If used in clinical practice, PROs might identify women at highest risk for early discontinuation and allow for interventions to improve tolerance before significant toxicities develop. Further research is needed to improve capturing PROs in routine clinical practice.
Collapse
Affiliation(s)
- Kunal C Kadakia
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
| | - Claire F Snyder
- Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
| | - Kelley M Kidwell
- Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA
| | - Nicholas J Seewald
- Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan, USA
| | - David A Flockhart
- Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Todd C Skaar
- Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Zereunesay Desta
- Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - James M Rae
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
| | - Julie L Otte
- Indiana University School of Nursing, Indianapolis, Indiana, USA
| | | | - Anna M Storniolo
- Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Daniel F Hayes
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
| | - Vered Stearns
- Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA
| | - N Lynn Henry
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
| |
Collapse
|
29
|
Mioranza E, Falci C, Dieci MV, Guarneri V, Conte P. The impact of adjuvant endocrine therapy in early breast cancer on quality-of-life: an overview of prospective trials. ACTA ACUST UNITED AC 2016. [DOI: 10.1080/23809000.2016.1157002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Eleonora Mioranza
- Division of Medical Oncology II, Veneto Istitute of Oncology IOV – IRCCS, Padua, Italy
| | - Cristina Falci
- Division of Medical Oncology II, Veneto Istitute of Oncology IOV – IRCCS, Padua, Italy
| | - Maria Vittoria Dieci
- Division of Medical Oncology II, Veneto Istitute of Oncology IOV – IRCCS, Padua, Italy
- Departement of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
| | - Valentina Guarneri
- Division of Medical Oncology II, Veneto Istitute of Oncology IOV – IRCCS, Padua, Italy
- Departement of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
| | - Pierfranco Conte
- Division of Medical Oncology II, Veneto Istitute of Oncology IOV – IRCCS, Padua, Italy
- Departement of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
| |
Collapse
|
30
|
Tachi T, Teramachi H, Tanaka K, Asano S, Osawa T, Kawashima A, Hori A, Yasuda M, Mizui T, Nakada T, Noguchi Y, Tsuchiya T, Goto C. The impact of side effects from outpatient chemotherapy on presenteeism in breast cancer patients: a prospective analysis. SPRINGERPLUS 2016; 5:327. [PMID: 27064454 PMCID: PMC4791447 DOI: 10.1186/s40064-016-1979-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Accepted: 03/06/2016] [Indexed: 11/15/2022]
Abstract
In the field of occupational health services, productivity loss can be expressed by absenteeism (i.e., employees being absent from work and taking leave due to health problems) and presenteeism (i.e., a reduction in the ability to perform one’s tasks at work). Similar to absenteeism, it is important to assess presenteeism because it can severely reduce productivity. Despite numerous reports about the impact of disease and medical treatments on presenteeism, there is a lack of data regarding the influence of medication side effects. In this study, a prospective analysis was conducted via questionnaire survey to clarify the influence of the side effects of anticancer drugs on presenteeism in workers receiving outpatient chemotherapy for breast cancer. Between December 2012 and November 2013, the influence of side effects on the quality of life, absenteeism, and presenteeism was investigated via a questionnaire conducted before and after 1 course of chemotherapy in 19 currently employed breast cancer patients receiving outpatient chemotherapy for the first time at Gifu Municipal Hospital, Japan. The rate of absenteeism was 24.7 %, resulting in financial losses of 2002 yen/day (national statistical data) and 881 yen/day (our questionnaire data). The rate of presenteeism was 33.7 %, resulting in financial losses of 1354 yen/day (national statistical data) and 1263 yen/day (our questionnaire data). Furthermore, a significant positive correlation was observed between absenteeism and presenteeism (r = 0.687, p = 0.001), suggesting that the productivity losses associated with presenteeism due to the side effects of anticancer drugs in breast cancer patients are large and similar to that associated with absenteeism in these patients. Our results may be useful for improving the occupational health of workers receiving chemotherapy for cancer.
Collapse
Affiliation(s)
- Tomoya Tachi
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4, Daigakunishi, Gifu-shi, Gifu, 501-1196 Japan ; Department of Pharmacy, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu-shi, Gifu, 500-8513 Japan
| | - Hitomi Teramachi
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4, Daigakunishi, Gifu-shi, Gifu, 501-1196 Japan
| | - Kazuhide Tanaka
- Department of Pharmacy, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu-shi, Gifu, 500-8513 Japan
| | - Shoko Asano
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4, Daigakunishi, Gifu-shi, Gifu, 501-1196 Japan
| | - Tomohiro Osawa
- Department of Pharmacy, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu-shi, Gifu, 500-8513 Japan
| | - Azusa Kawashima
- Department of Pharmacy, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu-shi, Gifu, 500-8513 Japan
| | - Akiyo Hori
- Department of Pharmacy, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu-shi, Gifu, 500-8513 Japan
| | - Masahiro Yasuda
- Department of Pharmacy, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu-shi, Gifu, 500-8513 Japan
| | - Takashi Mizui
- Department of Pharmacy, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu-shi, Gifu, 500-8513 Japan
| | - Takumi Nakada
- Department of Breast Surgery, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu-shi, Gifu, 500-8513 Japan
| | - Yoshihiro Noguchi
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, 1-25-4, Daigakunishi, Gifu-shi, Gifu, 501-1196 Japan
| | - Teruo Tsuchiya
- Community Health Support and Research Center, 15 Takehana-cho Nishikimachi, Hashima-shi, Gifu, 501-6242 Japan
| | - Chitoshi Goto
- Department of Pharmacy, Gifu Municipal Hospital, 7-1 Kashima-cho, Gifu-shi, Gifu, 500-8513 Japan
| |
Collapse
|
31
|
Ganz PA, Petersen L, Bower JE, Crespi CM. Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study. J Clin Oncol 2016; 34:816-24. [PMID: 26786934 DOI: 10.1200/jco.2015.64.3866] [Citation(s) in RCA: 69] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To examine patterns of health and symptoms associated with the initiation of adjuvant endocrine therapy (ET) for primary breast cancer treatment. PATIENTS AND METHODS The mind-body study (MBS) observational cohort participants provided self-reported data on physical and mental health, ET-related symptoms, as well as depression, fatigue, and sleep obtained at enrollment (after primary treatment, prior to initiation of ET) and 6 and 12 months later. Longitudinal trajectories of outcome variables among three patient groups (no ET, aromatase inhibitor [AI], or tamoxifen) were compared by using linear mixed models. RESULTS Two-thirds of the 186 women initiated ET, which was evenly split between AI and tamoxifen, and no significant differences were observed in self-reported measures among the groups at baseline or in covariate-adjusted analyses. Physical health scores were below normative levels initially and improved over time, but the AI group had a significantly lower score at 12 months (P = .05); mental health scores were within the normal range, were similar in each group, and did not change over time. The no-ET group showed either stable or declining symptom severity, whereas the ET groups often showed increased severity over time, and the AI group reported more severe musculoskeletal (P = .02), hot flash (P = .02), and cognitive problems (P = .006) at one or both of the follow-up time points compared with the no-ET group. The tamoxifen group had higher levels of hot flashes (P = .002), cognitive problems (P = .016), and bladder problems (P = .02) than the no-ET group. CONCLUSION Attention should be given to the increased symptom burden associated with ET, and better efforts should be made to address patient-reported outcomes.
Collapse
Affiliation(s)
- Patricia A Ganz
- All authors: University of California, Los Angeles, Los Angeles, CA.
| | - Laura Petersen
- All authors: University of California, Los Angeles, Los Angeles, CA
| | - Julienne E Bower
- All authors: University of California, Los Angeles, Los Angeles, CA
| | | |
Collapse
|
32
|
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 2015; 16:848-58. [PMID: 26092816 DOI: 10.1016/s1470-2045(15)00049-2] [Citation(s) in RCA: 110] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2015] [Revised: 04/22/2015] [Accepted: 04/23/2015] [Indexed: 11/20/2022]
Abstract
BACKGROUND The combined efficacy analysis of the TEXT and SOFT trials showed a significant disease-free survival benefit with exemestane plus ovarian function suppression (OFS) compared with tamoxifen plus OFS. We present patient-reported outcomes from these trials. METHODS Between Nov 7, 2003, and April 7, 2011, 4717 premenopausal women with hormone-receptor positive breast cancer were enrolled in TEXT or SOFT to receive unmasked adjuvant treatment with 5 years of exemestane plus OFS or tamoxifen plus OFS. Gonadotropin-releasing hormone analogue triptorelin, bilateral oophorectomy, or bilateral ovarian irradiation were used to achieve OFS. Chemotherapy use was optional. Randomisation with permuted blocks was done with the International Breast Cancer Study Group's internet-based system and was stratified by chemotherapy use and status of lymph nodes. Patients completed a quality of life (QoL) form comprising several global and symptom indicators at baseline, every 6 months for 24 months, and then every year during years 3 to 6. Differences in the change of QoL from baseline between the two treatments were tested at 6 months, 24 months, and 60 months with mixed-models for repeated measures for each trial with and without chemotherapy and overall. The analysis was by intention to treat. At the time of analysis, the median follow-up was 5·7 years (IQR 3·7-6·9); treatment and follow-up of patients continue. The trials are registered with ClinicalTrials.gov, as NCT00066703 (TEXT) and NCT00066690 (SOFT). FINDINGS Patients on tamoxifen plus OFS were more affected by hot flushes and sweats over 5 years than were those on exemestane plus OFS, although these symptoms improved. Patients on exemestane plus OFS reported more vaginal dryness, greater loss of sexual interest, and difficulties becoming aroused than did patients on tamoxifen plus OFS; these differences persisted over time. An increase in bone or joint pain was more pronounced, particularly in the short term, in patients on exemestane plus OFS than patients on tamoxifen plus OFS. Changes in global QoL indicators from baseline were small and similar between treatments over the 5 years. INTERPRETATION Overall, from a QoL perspective, there is no strong indication to favour either exemestane plus OFS or tamoxifen plus OFS. The distinct effects of the two treatments on the burden of endocrine symptoms need to be addressed with patients individually. FUNDING Pfizer, International Breast Cancer Study Group, and US National Cancer Institute.
Collapse
|
33
|
Abstract
INTRODUCTION Aromatase inhibitor (AI) therapy is the current preferred choice of endocrine therapy in postmenopausal estrogen receptor-positive breast cancer patients thanks to their improved effectiveness compared to tamoxifen. Despite the absence of increased endometrial pathology and deep venous thrombosis seen in tamoxifen-users, the safety profile of AIs consists of a variety of bothersome side effects negatively influencing daily functioning. AREAS COVERED Besides the well-known adverse effects on joints and bone and the vasomotor system, more neglected and latent toxicity like cognitive problems and vulvovaginal atrophy will be discussed. Concern has been raised in terms of increased risk of fractures and cardiovascular events with chronic AI use. EXPERT OPINION Placebo-controlled long-term studies carefully monitoring these adverse events, together with more extensive research in the etiologies, are warranted.
Collapse
|
34
|
Tachi T, Teramachi H, Tanaka K, Asano S, Osawa T, Kawashima A, Yasuda M, Mizui T, Nakada T, Noguchi Y, Tsuchiya T, Goto C. The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients. PLoS One 2015; 10:e0124169. [PMID: 25915539 PMCID: PMC4410996 DOI: 10.1371/journal.pone.0124169] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Accepted: 03/10/2015] [Indexed: 11/19/2022] Open
Abstract
The objective of our study was to clarify the impact of adverse events associated with the initial course of outpatient chemotherapy on the quality of life of breast cancer patients. We conducted a survey to assess the quality of life in 48 breast cancer patients before and after receiving their first course of outpatient chemotherapy at Gifu Municipal Hospital. Patients completed the European Quality of Life 5 Dimensions and Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs before and after 1 course of outpatient chemotherapy. European Quality of Life 5 Dimensions utility value and Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs total score decreased significantly after chemotherapy (p<0.001 and p = 0.018, respectively). The mean scores for the activity, physical condition, and psychological condition subscales of the Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs decreased significantly after chemotherapy (p = 0.003, p<0.001, and p = 0.032, respectively), whereas the social relationships score increased significantly (p<0.001). Furthermore, in the evaluation of quality of life according to individual adverse events, the decrease in quality of life after chemotherapy in terms of the European Quality of Life 5 Dimensions utility value and the Quality of Life Questionnaire for Cancer Patients Treated with Anticancer Drugs total score was greater in anorexic patients than in non-anorexic patients (p = 0.009 and p<0.001, respectively). This suggests that anorexia greatly reduces quality of life. Our findings reveal that anticancer drug-related adverse events, particularly anorexia, reduce overall quality of life following the first course of outpatient chemotherapy in current breast cancer patients. These findings are extremely useful and important in understanding the impact of anticancer drug-related adverse events on quality of life.
Collapse
Affiliation(s)
- Tomoya Tachi
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan
- Department of Pharmacy, Gifu Municipal Hospital, Gifu, Japan
| | - Hitomi Teramachi
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan
- * E-mail:
| | - Kazuhide Tanaka
- Department of Pharmacy, Gifu Municipal Hospital, Gifu, Japan
| | - Shoko Asano
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan
| | - Tomohiro Osawa
- Department of Pharmacy, Gifu Municipal Hospital, Gifu, Japan
| | - Azusa Kawashima
- Department of Pharmacy, Gifu Municipal Hospital, Gifu, Japan
| | - Masahiro Yasuda
- Department of Pharmacy, Gifu Municipal Hospital, Gifu, Japan
| | - Takashi Mizui
- Department of Pharmacy, Gifu Municipal Hospital, Gifu, Japan
| | - Takumi Nakada
- Department of Breast Surgery, Gifu Municipal Hospital, Gifu, Japan
| | - Yoshihiro Noguchi
- Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan
| | - Teruo Tsuchiya
- Community Health Support and Research Center, Gifu, Japan
| | - Chitoshi Goto
- Department of Pharmacy, Gifu Municipal Hospital, Gifu, Japan
| |
Collapse
|
35
|
Ochayon L, Tunin R, Yoselis A, Kadmon I. Symptoms of hormonal therapy and social support: Is there a connection? Comparison of symptom severity, symptom interference and social support among breast cancer patients receiving and not receiving adjuvant hormonal treatment. Eur J Oncol Nurs 2014; 19:260-7. [PMID: 25529935 DOI: 10.1016/j.ejon.2014.11.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Revised: 10/23/2014] [Accepted: 11/16/2014] [Indexed: 01/11/2023]
Abstract
BACKGROUND Although there has been a significant reduction in mortality, breast cancer is the most frequent cancer among women worldwide. This decline in mortality has created a significant survivor population that must manage the post curative treatment phase, in order to have an increased quality of life and well-being. This study examined the relationship between symptom interference and severity with the perception of social support in the lives of women receiving or not receiving, hormonal therapy after initial treatment. METHODS AND SAMPLE Participants completed symptom severity and interference questionnaires, (MDASI and BCPT), a social support survey (MSPSS) and demographic and comorbidity questionnaires. RESULTS Of the 210 women participants, higher symptom severity correlated with unemployment, living alone or being religious. Participants who were currently taking hormonal treatment (n = 84), reported a significant negative correlation between symptom severity, measured by MDASI, and social support (p = 0.006). Consequently, as symptom severity increased, perceived social support decreased. In the BCPT assessment, decreased cognitive functioning (p < 0.05), pain (p < 0.05), bladder dysfunction (p = 0.001), and reduced self-image (p < 0.01) were significantly negatively correlated with social support for those participants currently taking hormonal therapy. Participants who had not previously received hormonal therapy (n = 64), cognitive dysfunction and bladder dysfunction were negatively correlated with social support. Women with preexisting heart or pulmonary dysfunction and arthritis reported statistically significant higher levels of symptom severity and decreased perceptions of social support. CONCLUSIONS Identifying socio-demographic variables and comorbidities that affect hormonal therapy symptom burden is essential for offering adequate support for breast cancer survivors.
Collapse
Affiliation(s)
- Lea Ochayon
- Radiotherapy Unit and Oncology Clinic, Hadassah Medical Organization, Jerusalem, Israel.
| | - Rina Tunin
- Henrietta Szold Hadassah Hebrew University School of Nursing, Jerusalem, Israel; Hadassah Medical Organization, Jerusalem, Israel
| | | | - Ilana Kadmon
- Henrietta Szold Hadassah Hebrew University School of Nursing, Jerusalem, Israel; Hadassah Medical Organization, Jerusalem, Israel
| |
Collapse
|
36
|
Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 2014; 33:1104-11. [PMID: 25452437 DOI: 10.1200/jco.2014.57.1547] [Citation(s) in RCA: 210] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
PURPOSE Arthralgia occurs in up to 50% of breast cancer survivors treated with aromatase inhibitors (AIs) and is the most common reason for poor AI adherence. We conducted, in 121 breast cancer survivors receiving an AI and reporting arthralgia, a yearlong randomized trial of the impact of exercise versus usual care on arthralgia severity. PATIENTS AND METHODS Eligibility criteria included receiving an AI for at least 6 months, reporting ≥ 3 of 10 for worst joint pain on the Brief Pain Inventory (BPI), and reporting < 90 minutes per week of aerobic exercise and no strength training. Participants were randomly assigned to exercise (150 minutes per week of aerobic exercise and supervised strength training twice per week) or usual care. The BPI, Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index, and Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire were completed at baseline and at 3, 6, 9, and 12 months. Intervention effects were evaluated using mixed-model repeated measures analysis, with change at 12 months as the primary end point. RESULTS Over 12 months, women randomly assigned to exercise (n = 61) attended 70% (± standard deviation [SD], 28%) of resistance training sessions and increased their exercise by 159 (± SD, 136) minutes per week. Worst joint pain scores decreased by 1.6 points (29%) at 12 months among women randomly assigned to exercise versus a 0.2-point increase (3%) among those receiving usual care (n = 60; P < .001). Pain severity and interference, as well as DASH and WOMAC pain scores, also decreased significantly at 12 months in women randomly assigned to exercise, compared with increases for those receiving usual care (all P < .001). CONCLUSION Exercise led to improvement in AI-induced arthralgia in previously inactive breast cancer survivors.
Collapse
Affiliation(s)
- Melinda L Irwin
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY.
| | - Brenda Cartmel
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Cary P Gross
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Elizabeth Ercolano
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Fangyong Li
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Xiaopan Yao
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Martha Fiellin
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Scott Capozza
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Marianna Rothbard
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Yang Zhou
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Maura Harrigan
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Tara Sanft
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Kathryn Schmitz
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Tuhina Neogi
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Dawn Hershman
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| | - Jennifer Ligibel
- Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Martha Fiellin, Scott Capozza, Marianna Rothbard, Yang Zhou, Maura Harrigan, and Tara Sanft, Yale University; Melinda L. Irwin, Brenda Cartmel, Cary P. Gross, Elizabeth Ercolano, Fangyong Li, Xiaopan Yao, Yang Zhou, and Tara Sanft, Yale Cancer Center, New Haven, CT; Kathryn Schmitz, University of Pennsylvania, Philadelphia, PA; Tuhina Neogi, Boston University School of Medicine; Jennifer Ligibel, Dana-Farber Cancer Institute, Boston, MA; and Dawn Hershman, Columbia University, New York, NY
| |
Collapse
|
37
|
Brennan ME, Butow P, Spillane AJ, Boyle F. Patient-reported quality of life, unmet needs and care coordination outcomes: Moving toward targeted breast cancer survivorship care planning. Asia Pac J Clin Oncol 2014; 12:e323-31. [PMID: 25244662 DOI: 10.1111/ajco.12254] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/01/2014] [Indexed: 11/27/2022]
Abstract
AIM Survivorship care plans (SCPs) have been proposed for universal use with the aim of addressing the many unmet needs of cancer survivors. Trials have failed to find a significant impact of SCPs on quality of life outcomes. This study evaluated quality of life, unmet needs, satisfaction with health care and perception of cancer care coordination at the end of treatment in a cohort of women at the end of treatment for early breast cancer. The aim was to identify specific needs to assist in the design of a tailored SCP. METHODS Women completed patient-reported measures of health-related quality of life (FACT-B [ES]), unmet needs (CaSUN), satisfaction with medical care and cancer care coordination. Total scores and subscale scores for the whole cohort and results of analysis comparing three age groups were reported. RESULTS Sixty-eight women (mean age 56) participated. Mean score for FACT-B = 108 and FACT-B (ES) = 167.4. Younger women (<51 years) reported a significantly lower quality of life (P = 0.001 for FACT-B, TOI and FACT-B [ES]). Using CaSUN, 76.1% of participants reported at least one unmet need; mean number of unmet needs = 6.2. Younger women reported more unmet needs than older women. The most frequently reported unmet need was fear of cancer recurrence. Overall, participants were very satisfied with medical care and cancer care coordination. CONCLUSION Younger women reported poorer quality of life and more unmet needs. SCPs should specifically target younger women and must include strategies to address fear of cancer recurrence if they are to lead to a measureable difference in outcomes.
Collapse
Affiliation(s)
- Meagan Elizabeth Brennan
- Northern Clinical School, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.,The Patricia Ritchie Centre for Cancer Care and Research, The Mater Hospital, North Sydney, New South Wales, Australia
| | - Phyllis Butow
- Psycho-oncology Co-operative Research Group (PoCoG), The University of Sydney, Sydney, New South Wales, Australia
| | - Andrew John Spillane
- Northern Clinical School, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.,Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia
| | - Frances Boyle
- Northern Clinical School, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.,The Patricia Ritchie Centre for Cancer Care and Research, The Mater Hospital, North Sydney, New South Wales, Australia
| |
Collapse
|
38
|
Neuner JM, Zokoe N, McGinley EL, Pezzin LE, Yen TWF, Schapira MM, Nattinger AB. Quality of life among a population-based cohort of older patients with breast cancer. Breast 2014; 23:609-16. [PMID: 25034932 DOI: 10.1016/j.breast.2014.06.002] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2013] [Revised: 05/06/2014] [Accepted: 06/05/2014] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND Growing numbers of older women receive adjuvant breast cancer therapies, but little is known about the long-term effects of current therapies upon health-related quality of life outside of clinical trials. METHODS A population-based cohort of postmenopausal women with incident breast cancer aged sixty-five and older was identified from Medicare claims from four states and followed over five years. General health-related quality of life (HRQOL) was assessed using the Medical Outcomes Study SF-12 Health Survey, and breast cancer-related HRQOL was assessed using the breast cancer subscale of the functional assessment of cancer therapy (FACT-B BCS). The association of HRQOL with sociodemographic variables, comorbidity, and breast cancer variables (stage, treatments, and treatment sequelae) was examined in longitudinal models. RESULTS Among the 3083 older breast cancer survivors, general HRQOL as measured by SF-12 mental and physical component scores was similar to norms for non-cancer populations, and remained stable throughout follow-up. Breast cancer treatments, including surgery and radiation, adjuvant hormonal therapy, and cytotoxic chemotherapy were not associated with worsened general health scores. A similar pattern was seen for breast cancer-related HRQOL scores, except that chemotherapy was associated with slightly worse scores. Lymphedema occurred in 17% of the cohort, and was strongly associated with all measures of HRQOL. Reductions in general HRQOL with lymphedema development were larger than those with an age increase of 10 years. CONCLUSIONS There is little association of breast cancer treatment with HRQOL in older breast cancer patients followed for up to five years, but the development of lymphedema is associated with substantial reductions in HRQOL.
Collapse
Affiliation(s)
- Joan M Neuner
- Medical College of Wisconsin, Department of Medicine, 9200 W Wisconsin Avenue, Milwaukee, WI 53226, USA; Center for Patient Care and Outcomes Research, 8701 Watertown Plank Road, Suite H3100, Milwaukee, WI 53226, USA.
| | - Nathan Zokoe
- Center for Patient Care and Outcomes Research, 8701 Watertown Plank Road, Suite H3100, Milwaukee, WI 53226, USA
| | - Emily L McGinley
- Center for Patient Care and Outcomes Research, 8701 Watertown Plank Road, Suite H3100, Milwaukee, WI 53226, USA
| | - Liliana E Pezzin
- Medical College of Wisconsin, Department of Medicine, 9200 W Wisconsin Avenue, Milwaukee, WI 53226, USA; Center for Patient Care and Outcomes Research, 8701 Watertown Plank Road, Suite H3100, Milwaukee, WI 53226, USA
| | - Tina W F Yen
- Medical College of Wisconsin, Department of Surgical Oncology, 9200 W Wisconsin Avenue, Milwaukee, WI 53226, USA; Center for Patient Care and Outcomes Research, 8701 Watertown Plank Road, Suite H3100, Milwaukee, WI 53226, USA
| | - Marilyn M Schapira
- Perelman School of Medicine at the University of Pennsylvania, 295 John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104, USA
| | - Ann B Nattinger
- Medical College of Wisconsin, Department of Medicine, 9200 W Wisconsin Avenue, Milwaukee, WI 53226, USA; Center for Patient Care and Outcomes Research, 8701 Watertown Plank Road, Suite H3100, Milwaukee, WI 53226, USA
| |
Collapse
|
39
|
Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer. Breast Cancer Res Treat 2014; 145:155-64. [PMID: 24692082 DOI: 10.1007/s10549-014-2935-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2013] [Accepted: 03/21/2014] [Indexed: 10/25/2022]
Abstract
Trials of adjuvant endocrine therapy for breast cancer have shown that aromatase inhibitors have little impact on global health-related quality of life (HRQoL), but have significant effects on patient-reported endocrine symptoms (ESs). There are few studies of HRQoL and psychological distress during preoperative endocrine therapy performed to determine endocrine responsiveness. The NEOS trial is a multicenter, phase 3 randomized controlled trial in postmenopausal women with hormone receptor-positive breast cancer. The primary aim of the trial was to evaluate the need for adjuvant chemotherapy in patients with clinical T1c-T2N0M0, hormone receptor-positive tumors who responded to neoadjuvant letrozole (LET) administered for 24-28 weeks before surgery. The primary endpoint was disease-free survival and the secondary endpoints included adverse events, HRQoL, and cost-effectiveness. In a HRQoL sub-study, subjects were assessed at baseline and 4 and 16 weeks after starting neoadjuvant LET, using the functional assessment of cancer therapy-breast and its ES subscale, and the hospital anxiety and depression scale. HRQoL and psychosocial distress were analyzed in the uncontrolled phase during 24-28 weeks of neoadjuvant LET therapy in the NEOS trial. From May 16, 2008, to December 14, 2011, 503 patients were recruited into the HRQoL sub-study. The full analysis set included 497 patients with a mean age of 63-years old. The questionnaire response rates at enrollment and 4 and 16 weeks were 94.4, 90.7, and 89.1 %, respectively. There were no significant changes in the FACT-G or B-trial outcome index over time, but the social and family well-being score and the ES subscale deteriorated significantly, and the number of patients with clinically significant hot flush increased significantly. Anxiety, depression, and emotional well-being improved significantly after neoadjuvant LET. Neoadjuvant endocrine therapy with LET had no impact on global HRQoL, but did influence endocrine-related symptoms such as hot flush. This study is registered as UMIN000001090.
Collapse
|
40
|
Van Asten K, Neven P, Lintermans A, Wildiers H, Paridaens R. Aromatase inhibitors in the breast cancer clinic: focus on exemestane. Endocr Relat Cancer 2014; 21:R31-49. [PMID: 24434719 DOI: 10.1530/erc-13-0269] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Breast cancer is the most prevalent type of cancer in women and responsible for significant female cancer-related mortality worldwide. In the Western world, over 80% of breast cancers are hormone-receptor positive for which endocrine therapy is administered. The main anti-estrogen treatments in use consist of selective estrogen-receptor modulators, such as tamoxifen, and third-generation aromatase inhibitors (AIs), such as exemestane, letrozole, and anastrozole. In this review, the focus will lie on exemestane, its clinical use, and its side-effect profile. Exemestane is the only third-generation steroidal AI. Its efficacy as a first-line treatment in metastatic breast cancer has been demonstrated. Therefore, exemestane could be considered a valid first-line therapeutic option, but it also can be used in second-line or further situations. Exemestane is mostly used as part of sequential adjuvant treatment following tamoxifen, but in this setting it is also active in monotherapy. Furthermore, this AI has been studied in the neoadjuvant setting as presurgical treatment, and even as chemoprevention in high-risk healthy postmenopausal women. It may reverse side effects of tamoxifen, such as endometrial changes and thromboembolic disease but may also cause some inconvenient side effects itself. Additionally, there is a lack of total cross-resistance between exemestane and nonsteroidal AIs as far as their anti-tumoral efficacy is concerned; moreover the two classes of AIs display a nontotal overlapping toxicity profile. Taking together, exemestane can be considered as a useful treatment option at all stages of breast cancer.
Collapse
Affiliation(s)
- Kathleen Van Asten
- KU Leuven, Department of Oncology, Leuven, Belgium University Hospitals Leuven, Department of Gynecology and Obstetrics, Leuven, Belgium University Hospitals Leuven, Department of General Medical Oncology, Leuven, Belgium
| | | | | | | | | |
Collapse
|
41
|
Bao T, Cai L, Snyder C, Betts K, Tarpinian K, Gould J, Jeter S, Medeiros M, Chumsri S, Bardia A, Tan M, Singh H, Tkaczuk KHR, Stearns V. Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer 2013; 120:381-9. [PMID: 24375332 DOI: 10.1002/cncr.28352] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Revised: 07/29/2013] [Accepted: 08/02/2013] [Indexed: 11/08/2022]
Abstract
BACKGROUND Aromatase inhibitors (AIs) have been associated with decrements in patient-reported outcomes (PROs). The objective of this study was to assess whether real acupuncture (RA), compared with sham acupuncture (SA), improves PROs in patients with breast cancer who are receiving an adjuvant AI. METHODS Postmenopausal women with a stage 0 through III breast cancer who received an AI and had treatment-associated musculoskeletal symptoms were randomized to receive 8 weekly RA versus SA in a dual-center, randomized controlled trial. The National Surgical Adjuvant Breast and Bowel Project (NSABP) menopausal symptoms questionnaire, the Center for Epidemiological Studies Depression (CESD) scale, the Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index (PSQI), the hot flash daily diary, the Hot Flash-Related Daily Interference Scale (HFRDI), and the European quality-of-life survey (EuroQol) were used to assess PROs at baseline and at 4weeks, 8 weeks, and 12 weeks. RESULTS The intention-to-treat analysis included 23 patients in the RA arm and 24 patients in the SA arm. There were no significant differences in baseline characteristics between the 2 groups. Compared with baseline, scores in the RA arm improved significantly at week 8 on the CESD (P = .022), hot flash severity (P = .006), hot flash frequency (P = .011), the HFRDI (P = .014), and NSABP menopausal symptoms (P = .022); scores in the SA arm improved significantly on the EuroQol (P = .022),the HFRDI (P = .043), and NSABP menopausal symptoms (P = .005). Post-hoc analysis indicated that African American patients (n = 9) benefited more from RA than SA compared with non-African American patients (n = 38) in reducing hot flash severity (P < .001) and frequency (P < .001) scores. CONCLUSIONS Both RA and SA were associated with improvement in PROs among patients with breast cancer who were receiving AIs, and no significant difference was detected between arms. Racial differences in response to acupuncture warrant further study.
Collapse
Affiliation(s)
- Ting Bao
- University of Maryland Greenebaum Cancer Center, Baltimore, Maryland
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Kyvernitakis I, Ziller V, Hars O, Bauer M, Kalder M, Hadji P. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer. Climacteric 2013; 17:252-9. [DOI: 10.3109/13697137.2013.819327] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
43
|
Liu J, Flockhart PJ, Lu D, Lv W, Lu WJ, Han X, Cushman M, Flockhart DA. Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen. Drug Metab Dispos 2013; 41:1715-20. [PMID: 23824607 DOI: 10.1124/dmd.113.052506] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Aromatase catalyzes the conversion of testosterone to estradiol and is the main source of endogenous estrogen in postmenopausal women. Aromatase inhibitors (AIs) are used to treat postmenopausal women with hormone receptor-positive breast cancer. Norendoxifen [4-(1-(4-(2-aminoethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol], an active metabolite of the selective estrogen receptor modulator tamoxifen, has been shown to be a potent competitive AI, with an IC50 of 90 nM. To obtain data relevant to the clinical use of norendoxifen, the primary objective of this study was to investigate norendoxifen's inhibitory capability on enzymes related to drug-drug interactions. We determined the inhibitory ability of norendoxifen against important drug-metabolizing cytochrome P450 enzymes, including CYP1A2, CYP2A6, CYP3A4, CYP3A5, and CYP2C19, to establish the potency of norendoxifen as a potential cause of drug-drug interactions. A second objective was to determine the effects of E- and Z-norendoxifen on the inhibition of these enzymes to further characterize the isomers' selectivity. The inhibitory abilities of E-, mixed, and Z-norendoxifen against recombinant aromatase (CYP19), CYP1A2, CYP3A4, CYP3A5, and CYP2C19 were tested using microsomal incubations. Mixed norendoxifen inhibited these enzymes with Ki values of 70 ± 9, 76 ± 3, 375 ± 6, 829 ± 62, and 0.56 ± 0.02 nM, respectively. E-Norendoxifen had a 9.3-fold-higher inhibitory ability than Z-norendoxifen against CYP19, while E- and Z-norendoxifen had similar potencies against CYP1A2, CYP3A4, CYP3A5, and CYP2C19. These results suggest that norendoxifen is able to act as a potent AI, and that its E-isomer is 9.3-fold more potent than the Z-isomer.
Collapse
Affiliation(s)
- Jinzhong Liu
- Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indiana Institute for Personalized Medicine, Indianapolis, Indiana 46202, USA.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Sert F, Ozsaran Z, Eser E, Alanyalı SD, Haydaroglu A, Aras A. Quality of life assessment in women with breast cancer: a prospective study including hormonal therapy. J Breast Cancer 2013; 16:220-8. [PMID: 23843857 PMCID: PMC3706870 DOI: 10.4048/jbc.2013.16.2.220] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Accepted: 05/29/2013] [Indexed: 12/04/2022] Open
Abstract
Purpose Evaluating the effect of hormonal treatment on quality of life (QoL) in breast cancer patients by using the Functional Assessment of Cancer Treatment (FACT) questionnaire is the main purpose of this trial. Methods Breast cancer patients treated with adjuvant between January 2007 and December 2009 were evaluated. The first survey was done after patients completed their whole adjuvant treatment except for the hormonal therapy and this was as 'basal assessment.' The second survey was done 6 to 12 months after the basal surveys during their routine policlinic controls. The last survey was done within the last 18 to 24 months of the follow-up period. Results The effect of marital status, number of pregnancies, residence in the village or city, hemoglobin levels, chemotherapy and hormonal therapy for any other reason except for breast cancer on the QoL could not be seen. Endocrine subscale scores were detected to be higher in patients aged >60 years than in younger ones. The other dimension scores were low in the elderly patient group. There was a statistically significant relationship between being >30 years old and improvement in the social well-being score (p=0.028). The functional well-being scores were found to be significantly higher in the patient group that had no comorbid disease (p=0.018). Endocrine subscale scores were statistically worse in patients who had psychiatric disease (p=0.057) but the general QoL data were similar with others. It was shown that all QoL scores for all dimensions had statistically significant changes (p<0.001) in terms of hormonal regimes. Conclusion The diagnosis of breast cancer was found to be an independent factor that affects social well-being and social life in a negative way. We must give attention to complaints including complaints about sexual life and hormonal status in order to ensure compliance of patients with the required hormonal regimens. By the help of future research, we can improve the prognosis of this disease through increased treatment adherence and belief of patients.
Collapse
Affiliation(s)
- Fatma Sert
- Department of Radiation Oncology, Van Regional Training and Research Hospital, Van, Turkey. ; Department of Radiation Oncology, Medical School of Ege University, Izmir, Turkey
| | | | | | | | | | | |
Collapse
|
45
|
|
46
|
|
47
|
Walker GA, Xenophontos M, Chen LC, Cheung KL. Long-term efficacy and safety of exemestane in the treatment of breast cancer. Patient Prefer Adherence 2013; 7:245-58. [PMID: 23569364 PMCID: PMC3616141 DOI: 10.2147/ppa.s42223] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Exemestane, a steroidal aromatase inhibitor, is licensed for postmenopausal patients with estrogen receptor (ER)-positive breast cancer as second-line therapy in metastatic disease following antiestrogen failure and as part of sequential adjuvant therapy following initial tamoxifen. This study is a systematic literature review, evaluating exemestane in different clinical settings. The Ovid Medline (1948-2012), Embase (1980-2012), and Web of Science (1899-2012) databases were searched. Forty-two relevant articles covering randomized controlled trials were reviewed for efficacy and safety, and three for adherence. With regard to efficacy in metastatic disease, exemestane is superior to megestrol acetate after progression on tamoxifen. There is evidence for noninferiority to fulvestrant (following a prior aromatase inhibitor) and to nonsteroidal aromatase inhibitors in the first-line setting. Combined use with everolimus is shown to be more efficacious than exemestane alone following previous aromatase inhibitor use. In the adjuvant setting, a switch to exemestane after 2-3 years of tamoxifen is superior to 5 years of tamoxifen. Exemestane is noninferior to 5 years of tamoxifen as upfront therapy, and may have a role as an extended adjuvant therapy. Used as neoadjuvant therapy, increased breast conservation is achievable. As chemoprevention, exemestane significantly reduces the incidence of breast cancer in "at-risk" postmenopausal women. Exemestane is associated with myalgias and arthralgias, as well as reduced bone mineral density and increased risk of fracture, which do not appear to persist at follow-up, with subsequent return to pretreatment values. Compared with tamoxifen, there is a reduced incidence of endometrial changes, thromboembolic events, and hot flashes. Limited evidence shows nonadherence in 23%-32% of patients. Evidence is growing in support of exemestane in all clinical settings. It is generally more efficacious and has a better safety profile than tamoxifen. How it compares with the nonsteroidal aromatase inhibitors remains to be established. Further studies are required on adherence to ensure that maximum benefit is obtained.
Collapse
Affiliation(s)
- GA Walker
- Clinical Oncology, East Midlands Deanery, University of Nottingham, Nottingham, UK
| | - M Xenophontos
- Breast Surgery, School of Graduate Entry Medicine and Health, University of Nottingham, Nottingham, UK
| | - LC Chen
- Medicine Use, School of Pharmacy, University of Nottingham, Nottingham, UK
| | - KL Cheung
- Breast Surgery, School of Graduate Entry Medicine and Health, University of Nottingham, Nottingham, UK
- Correspondence: Kwok-Leung Cheung Division of Breast Surgery, School of Graduate Entry Medicine and Health, University of Nottingham, Royal Derby Hospital Centre, Uttoxeter Road, Derby DE22 3DT, UK Tel +44 1332 724 881 Fax +44 1332 724 880 Email
| |
Collapse
|
48
|
Abstract
Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cancer. Recently, the National Cancer Institute of Canada Clinical Trials Group MAP.3 study evaluated exemestane as a breast cancer prevention agent for women with specified higher risks of developing breast cancer. We review the history of exemestane and evaluate the available evidence of its use for breast cancer prevention.
Collapse
Affiliation(s)
- Jennifer Keating Litton
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA
| | | | | |
Collapse
|
49
|
Current status and future perspectives of patient-reported outcome research in clinical trials for patients with breast cancer in Japan. Breast Cancer 2012; 20:296-301. [PMID: 22569680 DOI: 10.1007/s12282-012-0368-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2012] [Accepted: 03/26/2012] [Indexed: 01/22/2023]
Abstract
The aim of healthcare providers is to help patients regain their health and/or maintain or increase their happiness. The quality of healthcare can be assessed objectively by using indices such as survival rates, but subjective assessment is sometimes more important than objective evaluation, because whether patients feel healthy or happy or not is their major concern. Quality of life (QOL) research is a typical approach to subjective assessment of health. Self-administered health-related QOL (HRQOL) questionnaires are used to obtain patient-reported outcome (PRO) data. PRO is defined by the US Food and Drug Administration (FDA) as any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else. PRO data are regarded as more accurate than clinician-rated ones in terms of assessing patients' symptoms and HRQOL. The Comprehensive Support Project for Health Outcome Research of the Public Health Research Foundation has conducted much PRO research in collaboration with the Comprehensive Support Project for Oncology Research, especially in randomized controlled trials (RCTs). Here, we review the results of PRO research in RCTs conducted in Japan and examine future perspectives in this field.
Collapse
|
50
|
van Nes JGH, Fontein DBY, Hille ETM, Voskuil DW, van Leeuwen FE, de Haes JCJM, Putter H, Seynaeve C, Nortier JWR, van de Velde CJH. Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study. Breast Cancer Res Treat 2012; 134:267-76. [PMID: 22453754 PMCID: PMC3397233 DOI: 10.1007/s10549-012-2028-2] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2012] [Accepted: 03/08/2012] [Indexed: 01/13/2023]
Abstract
Tamoxifen and aromatase inhibitors are associated with side effects which can significantly impact quality of life (QoL). We assessed QoL in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial and compared these data with reported adverse events in the main database. 2,754 Dutch postmenopausal early breast cancer patients were randomized between 5 years of exemestane, or tamoxifen (2.5–3 years) followed by exemestane (2.5–2 years). 742 patients were invited to participate in the QoL side study and complete questionnaires at 1 (T1) and 2 (T2) years after start of endocrine treatment. Questionnaires comprised the EORTC QLQ-C30 and BR23 questionnaires, supplemented with FACT-ES questions. 543 patients completed questionnaires at T1 and 454 patients (84 %) at T2. Overall QoL and most functioning scales improved over time. The only clinically relevant and statistically significant difference between treatment types concerned insomnia; exemestane-treated patients reported more insomnia than tamoxifen-treated patients. Discrepancy was observed between QoL issue scores reported by the patients and adverse events reported by physicians. Certain QoL issues are treatment- and/or time-specific and deserve attention by health care providers. There is a need for careful inquiry into QoL issues by those prescribing endocrine treatment to optimize QoL and treatment adherence.
Collapse
Affiliation(s)
- J G H van Nes
- Department of Surgery, K6-R, Leiden University Medical Centre, P.O. Box 9600, 2300, RC, Leiden, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|